RNA-targeting ligands, their compositions, and methods of making and using same - Patents.com

A fragment-based screening strategy using SHAPE and MaP techniques identifies small molecule ligands with high affinity for RNA structures, addressing the challenge of efficiently targeting RNA molecules for therapeutic applications.

JP7594303B2Active Publication Date: 2024-12-04THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Patent Information

Application Number
JP2022507316
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-29
Filing Date
2020-08-05
Publication Date
2024-12-04
Estimated Expiration
2040-08-05

AI Technical Summary

Technical Problem

Current methods are limited in efficiently identifying small molecule ligands that bind to RNA molecules, particularly non-coding RNAs, which are promising therapeutic targets due to their role in regulating gene expression and disease states, necessitating the development of new techniques for rapid and efficient identification of such ligands.

Method used

A fragment-based screening strategy using selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) and SHAPE mutational profiling (MaP) to identify small molecule fragments that bind to target RNA structures, specifically TPP riboswitches, followed by structure-activity relationship (SAR) studies to design tethered fragment ligands with high nanomolar affinity.

Benefits of technology

This approach allows for the development of ligands with enhanced binding affinity to RNA structures, demonstrating the potential for modulating cellular conditions and diseases by targeting RNA molecules, and is applicable to various RNA structures beyond TPP riboswitches.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594303000063
    Figure 0007594303000063
  • Figure 0007594303000064
    Figure 0007594303000064
  • Figure 0007594303000065
    Figure 0007594303000065
Patent Text Reader

Abstract

The present disclosure is directed to compounds that bind to target RNA molecules, such as TPP riboswitches, compositions containing these compounds, and methods for making and using them. The compounds contain two structurally distinct fragments that bind to the target RNA at two different binding sites, thereby enabling the production of higher affinity five-binding ligands compared to compounds that bind only to a single RNA binding site.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure is directed to compounds that bind to target RNA molecules, such as TPP riboswitches, compositions that contain these compounds, and methods for making and using them. The compounds contain two structurally distinct fragments that bind to target RNA at two different binding sites, thereby allowing for the production of higher affinity binding ligands compared to compounds that only bind to a single RNA binding site.

[0002] Sequence Listing Citation References The material in the attached Sequence Listing is incorporated by reference in its entirety into this application. The attachment entitled Sequence Listing 39397600002_ST25 was created on Aug. 5, 2020 and is 4KB.

[0003] Government support This invention was made with Government support under Grant Nos. GM098662 and AI068462 awarded by the National Institutes of Health (NIH). The Government has certain rights in this invention. [Background technology]

[0004] Most small molecule ligands are developed primarily to manipulate biological systems by targeting proteins. Proteins have highly complex three-dimensional structures that are important for their proper function and contain cavities and pockets where small molecule ligands can bind. 1、2 The transcriptome is the set of all RNA molecules produced within an organism and also contains promising targets for studying and manipulating biological systems. For example, RNA transcriptomes not only play an important role in mammalian systems, but are also present in both bacteria and viruses and therefore represent targets for small molecules to modulate gene expression.

[0005] RNA is a key feature required for the development of highly selective ligands 4 can adopt three-dimensional structures with a complexity comparable to that of proteins. 3 ,RNA plays a general role in governing the behavior of biological systems. 5 It should be noted that RNA is a carrier of genetic information that originally existed only to transmit messages for protein coding and to guide the process of protein integrity, but the modern view of RNA has evolved to encompass an expanded role, and a diverse range of RNA molecules are now understood to have a broad and profound role in regulating gene expression and other biological processes by various mechanisms. Even a large number of newly discovered non-coding RNAs have been found to be associated with diseases such as cancer and non-tumorigenic diseases. Thus, the realization that RNA contributes to disease states apart from coding for pathogenic proteins provides a wealth of previously unrecognized therapeutic targets.

[0006] However, it has been shown that small molecule ligands can bind to mRNA and potentially up- or down-regulate translation efficiency, thus modulating protein expression in cells. 6、7 However, there are challenges in identifying small RNA ligands that are not faced when targeting proteins. 4、11、12 This includes the development of small molecules directed at non-coding RNAs, which also represent a rich pool of targets. 8~10 Unfortunately, despite the development of various techniques for the analysis of RNA structure and the discovery of new functions, the ability to efficiently and rapidly identify or design inhibitors that bind to RNA and disrupt its function has lagged far behind. Therefore, there is a great need in the art to develop new methods and techniques that allow for the rapid and efficient identification of small molecule ligands that target RNA molecules. Summary of the Invention [Problem to be solved by the invention]

[0007] As already mentioned above, the transcriptome represents an attractive yet under-exploited set of targets for small molecule ligands. Small molecule ligands (and ultimately drugs) targeting messenger RNA and non-coding RNA have the potential to modulate cellular conditions and diseases. In this disclosure, a fragment-based screening strategy using selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) and SHAPE mutational profiling (MaP) RNA structure probing was used to develop small molecule fragments that bind to target RNA structures. In particular, fragments that bind to TPP riboswitches with millimolar to micromolar affinities and fragment pairs that bind cooperatively were identified. Structure-activity relationship (SAR) studies were performed to obtain information for efficiently designing linked fragment ligands that bind to TPP riboswitches with high nanomolar affinity. The principles from this disclosure are not meant to be limited to TPP riboswitches, but may be broadly applicable to other target RNA structures, taking advantage of cooperativity and multi-site binding to develop high-quality ligands for diverse RNA targets. [Means for solving the problem]

[0008] Thus, one aspect of the presently disclosed subject matter is a compound having a structure of formula (I): [ka] During the ceremony, X1, X2, and X3, in each occurrence, are independently selected from CR1, CHR1, N, NH, O, and S, and adjacent X1, X2, and X3 are not simultaneously selected to be O or S; The dashed line represents an optional double bond; Y1, Y2, and Y3, at each occurrence, are independently selected from CR2 and N; n is 1 or 2, and when n is 1, exactly one of the dashed lines is a double bond; L is [ka] is selected from wherein p, q, r, and v are independently selected from integers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; and z is selected from integers 1, 2, 3, 4, and 5; A is, [ka] is selected from wherein X4, X5, X6, and X7 are independently selected from CR3 and N; R1, R2, and R3 are independently selected from -H, -Cl, -Br, -I, -F, -CF3, -OH, -CN, -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -COOH, -COO(C1-C6 alkyl), -CO(C1-C6 alkyl), -O(C1-C6 alkyl), -OCO(C1-C6 alkyl), -NCO(C1-C6 alkyl), -CONH(C1-C6 alkyl), and substituted or unsubstituted C1-C6 alkyl; m is 1 or 2; W is -O or -NR4, where R4 is selected from -H, -CO(C1-C6 alkyl), substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, -CO(aryl), -CO(heteroaryl), and -CO(cycloalkyl); provided that at least two of X1, X2, X3, X4, X5, X6, and X7 are N; or a pharma- ceutically acceptable salt thereof.

[0009] Further aspects of the presently disclosed subject matter include compounds described herein that bind to a region of an RNA molecule.

[0010] Further aspects of the presently disclosed subject matter include compositions comprising a therapeutically effective amount of a compound described herein in a pharma- ceutically acceptable carrier, diluent, or excipient.

[0011] Further aspects of the presently disclosed subject matter include a method of treating a disease or disorder associated with dysfunction of RNA expression, the method comprising administering to a subject in need thereof a therapeutically effective amount of a dose of a composition of a compound described herein.

[0012] Further aspects of the presently disclosed subject matter include methods for making the compounds described herein.

[0013] Still further aspects of the presently disclosed subject matter are presented below. [Brief description of the drawings]

[0014] [Figure 1] Figure 1 shows a scheme of the RNA screening construct and fragment screening workflow. RNA motifs 1 and 2, the barcode helix, and the structural cassette helix are shown. RNA is probed using SHAPE in the presence or absence of small molecule fragments, and chemical modifications corresponding to ligand-dependent structural information are read out by multiplex MaP sequencing. [Diagram 2] Comparison of representative mutation rates for fragment hits and non-hits is shown. Normalized mutation rates for samples exposed to fragments are labeled +ligand, +2, or +4 and compared to traces without ligand labeled No Ligand. Statistically significant changes in mutation rate are indicated with a triangle (see Figure 8 for SHAPE validation data). (Top) Comparison of mutation rates for representative fragments that do not bind to test constructs. (Middle) Fragment that hits the TPP riboswitch region of the RNA. (Bottom) A non-specific hit that induces a change in reactivity across test constructs. Landmarks for motifs 1 and 2 are indicated below the SHAPE profile. [Figure 3A-3B](FIG. 3A) A comparison of the structure of the TPP riboswitch bound by fragment 17 with (FIG. 3B) the native TPP ligand (2HOJ28). The RNA structure is shown in a similar orientation in each image. Hydrogen bonds between the ligand and the RNA are shown as dashed lines. [Figure 4A-4B] Thermodynamic cycles and stepwise ligand binding affinities for fragments 2 and 31 are shown. Figure 4A shows a summary of binding by compound 2 (dark grey, K1) and compound 31 (light grey, K2) fragments. KD values ​​determined by ITC. Figure 4B shows ITC data showing single compound and cooperativity binding by fragments 2 and 31. Ligation of the two fragments shows an additive effect in binding energy, yielding compound 37 (KL), a submicromolar ligand. The ITC traces are shown with the background trace (ligand titrated in buffer) as light grey and the experimental trace in dark grey. Curve fitting is shown with 95% confidence intervals in grey shading. [Diagram 5] Covalent linkage of fragments 17 and 31 is shown as a function of linker type and length, end group chemical type, and end group orientation. Modifications that increase RNA binding affinity are present in compounds 36 and 37 (light grey), negative modifications are present in compounds 35, 39, and 40 (light grey), and neutral modifications are present in compound 38 (light grey). Dissociation constants determined by ITC. [Figure 6] Comparison of fragment-linker-fragment ligands developed by the fragment-based method, ordered by their linkage coefficient (E). Values ​​displayed on a logarithmic axis. Cooperative linkages correspond to lower E values ​​(top of vertical axis). Fragment 37 shows an E value of 2.5, and an LE value of 0.34. Dissociation constants of the individual fragments (left, center) and the linked ligand (right) are shown below the constituent fragments, with E values ​​(top) and ligand efficiencies (bottom). Covalent linkages introduced between fragments are highlighted in light grey. The structures of the constituent fragments are detailed in Table 7. [Figure 7A-7B]Screening construct design is shown. Figure 7A shows an RNA sequence (SEQ ID NO: 6) with the following components: GGUCGCGAGUAAUCGCGACC (SEQ ID NO: 7) is a structural cassette;

number

number

number

[0015] The subject matter of the present disclosure will be described in more detail below in this specification. However, many modifications and other embodiments of the subject matter of the present disclosure described herein will occur to those skilled in the art to which the subject matter of the present disclosure pertains, having the benefit of the teachings presented in the preceding description. Therefore, it should be understood that the subject matter of the present disclosure should not be limited to the specific embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein covers all alternatives, modifications, and equivalents. In the event that one or more of the incorporated documents, patents, and similar materials differ from or conflict with this application, including but not limited to defined terms, use of terms, described techniques, and the like, this application controls. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

[0016] definition As used herein, the term "alkyl group" refers to a saturated hydrocarbon radical containing 1-8, 1-6, 1-4, or 5-8 carbons. In some embodiments, the saturated radical contains more than 8 carbons. An alkyl group removes one hydrogen from an acyclic alkane and is thus structurally similar to an acyclic alkane compound modified by the substitution of a non-hydrogen group or radical. An alkyl group radical may be branched or unbranched. Lower alkyl group radicals have 1-4 carbon atoms. Higher alkyl group radicals have 5-8 carbon atoms. Examples of alkyl, lower alkyl, and higher alkyl group radicals include, but are not limited to, radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, amyl, t-amyl, n-pentyl, n-hexyl, i-octyl, and the like.

[0017] As used herein, the designations "(CO)" and "C(O)" are used to denote a carbonyl moiety. Examples of suitable carbonyl moieties include, but are not limited to, ketone and aldehyde moieties.

[0018] The term "cycloalkyl" refers to a hydrocarbon having 3-8 ring members, or 3-7 ring members, or 3-6 ring members, or 3-5 ring members, or 3-4 ring members, and may be monocyclic or bicyclic. The ring may be saturated or have some degree of unsaturation. A cycloalkyl group may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a cycloalkyl group may be substituted by a substituent. Representative examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.

[0019] The term "aryl" refers to a hydrocarbon monocyclic, bicyclic or tricyclic aromatic ring system. An aryl group may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, 4, 5, or 6 atoms of each ring of an aryl group may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like.

[0020] The term "heteroaryl" refers to an aromatic 5-10 membered ring system in which the heteroatoms are selected from O, N, or S, and the remaining ring atoms are carbon (with appropriate hydrogen atoms unless otherwise indicated). Heteroaryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted by a substituent. Examples of heteroaryl groups include pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl, indazolyl, and the like.

[0021] As used herein, the term "substituted" refers to a moiety (e.g., heteroaryl, aryl, alkyl, and / or alkenyl) that is bonded to one or more additional organic or inorganic substituent radicals. In some embodiments, the substituted moiety contains 1, 2, 3, 4, or 5 additional substituents or radicals. Suitable organic and inorganic substituent radicals include, but are not limited to, hydroxyl, cycloalkyl, aryl, substituted aryl, heteroaryl, heterocyclic ring, substituted heterocyclic ring, amino, monosubstituted amino, disubstituted amino, acyloxy, nitro, cyano, carboxy, carboalkoxy, alkylcarboxamido, substituted alkylcarboxamido, dialkylcarboxamido, substituted dialkylcarboxamido, alkylsulfonyl, alkylsulfinyl, thioalkyl, alkoxy, substituted alkoxy, or haloalkoxy radicals, as that term is defined herein. Unless otherwise specified herein, organic substituents may contain 1-4 or 5-8 carbon atoms. When a substituted moiety has more than one substituent radical attached thereto, the substituent radicals can be the same or different.

[0022] As used herein, the term "unsubstituted" refers to a moiety that is not bound to one or more additional organic or inorganic substituent radicals as described above (e.g., heteroaryl, aryl, alkenyl, and / or alkyl), meaning that such moiety is substituted only with hydrogen.

[0023] It will be understood that any recitation of structures and "substituted" or "substituted with" provided herein includes the implicit proviso that such structures and substitutions do not naturally undergo transformation, e.g., by rearrangement, cyclization, elimination, etc., in accordance with the allowed valences of the substituted atoms and substituents, and which result in stable compounds upon substitution.

[0024] As used herein, the term "RNA" refers to ribonucleic acid, a polymer molecule essential for a variety of biological roles in coding, decoding, regulation, and expression of genes. RNA and DNA are nucleic acids, which, along with lipids, proteins, and carbohydrates, constitute the four major macromolecules essential to all known forms of life. Like DNA, RNA is assembled as a chain of nucleotides, but unlike DNA, RNA is found in nature as a single strand folded on itself, rather than as a paired double strand. Cellular organisms use messenger RNA (mRNA) to transmit genetic information that directs the synthesis of specific proteins (using the nitrogenous bases guanine, uracil, adenine, and cytosine, denoted by the letters G, U, A, and C). Many viruses use RNA genomes to encode their genetic information. Some RNA molecules play active roles in cells by catalyzing biological reactions, controlling gene expression, or sensing and transmitting responses to cellular signals. One of these active processes is protein synthesis, a universal function in which RNA molecules direct the synthesis of proteins on ribosomes. This process uses transfer RNA (tRNA) molecules to deliver amino acids to the ribosome, which then links the amino acids together to form the encoded protein.

[0025] As used herein, the term "non-coding RNA (ncRNA)" refers to an RNA molecule that is not translated into protein. The DNA sequence from which functional non-coding RNA is transcribed is often called an RNA gene. Abundant and functionally important types of non-coding RNA include transfer RNA (tRNAs) and ribosomal RNA (rRNAs), as well as small RNAs, such as microRNA, siRNA, piRNA, snoRNA, snRNAs, exRNA, scaRNA, and long ncRNAs, such as Xist and HOTAIR.

[0026] As used herein, the term "coding RNA" refers to RNA that codes for a protein, i.e., messenger RNA (mRNA). Such RNA comprises the transcriptome.

[0027] As used herein, the term "riboswitch" refers to a regulatory segment of a messenger RNA molecule that binds a small molecule and alters the production of a protein encoded by the mRNA. Thus, an mRNA that contains a riboswitch is directly involved in regulating its own activity in response to the concentration of its effector molecule.

[0028] As used herein, the term "TPP riboswitch" refers to a highly conserved RNA secondary structure, also known as THI element and Thi-box riboswitch. It directly binds to thiamine pyrophosphate (TPP) and functions as a riboswitch that regulates gene expression through various mechanisms in archaea, bacteria and eukaryotes. TPP is the active form of thiamine (vitamin B1), an essential coenzyme synthesized by the coupling of pyrimidine and thiazole moieties in bacteria.

[0029] As used herein, the term "pseudoknot" refers to a nucleic acid secondary structure that contains at least two stem-loop structures in which one half of a stem is intercalated between the two halves of another stem. Pseudoknots were first recognized in Chinese cabbage yellow mosaic virus in 1982. Pseudoknots fold into a knot-shaped three-dimensional conformation, but are not true topological knots.

[0030] "Aptamer" refers to a nucleic acid molecule that can bind to a particular molecule of interest with high affinity and specificity (Tuerk and Gold, 1990; Ellington and Szostak, 1990) and can be either human engineered or naturally derived. Binding of a ligand to an aptamer, typically an RNA, changes the conformation of the aptamer and the nucleic acid in which the aptamer is located. In some cases, the change in conformation inhibits translation of the mRNA in which the aptamer is located or, for example, otherwise prevents normal activity of the nucleic acid. Aptamers may also be composed of DNA or contain non-natural nucleotides and nucleotide analogs. Aptamers will most typically be obtained by in vitro selection for binding of the target molecule. However, in vivo selection of aptamers is also possible. Aptamers are also the ligand-binding domain of riboswitches. Aptamers are typically about 10 to about 300 nucleotides in length. More typically, aptamers are about 30 to about 100 nucleotides in length. See, for example, U.S. Patent No. 6,949,379, which is incorporated herein by reference. Examples of aptamers useful in the present invention include, but are not limited to, PSMA aptamers (McNamara et al., 2006), CTLA4 aptamers (Santulli-Marotto et al., 2003), and 4-1BB aptamers (McNamara et al., 2007).

[0031] As used herein, the term "PCR" stands for polymerase chain reaction and refers to a method used widely in molecular biology to rapidly make hundreds to billions of copies of a particular DNA sample, allowing scientists to take a very small sample of DNA and amplify it into a large enough amount to study it in detail.

[0032] The phrase "pharmacologically acceptable" indicates that a substance or composition is chemically and / or toxicologically compatible with the formulation, including other ingredients, and / or the subject being treated therewith.

[0033] As used herein, the phrase "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the present invention. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate "mesylate", ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoic acid)) salts, alkali metal (e.g., sodium and potassium) salts, alkaline earth metal (e.g., magnesium) salts, and ammonium salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule, such as an acetate ion, a succinate ion, or other counterion. A counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. In addition, a pharmaceutically acceptable salt may have more than one charged atom in its structure. When multiple charged atoms are part of a pharmaceutically acceptable salt, the salt may have multiple counterions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.

[0034] As used herein, "carrier" includes pharma- ceutically acceptable carriers, excipients, or stabilizers that are non-toxic to cells or mammals exposed to it at the dosages and concentrations used. Often, physiologically acceptable carriers are pH-buffered aqueous solutions. Non-limiting examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids, antioxidants including ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine, or lysine, monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, salt-forming counterions such as sodium, and / or non-ionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®. In certain embodiments, the pharma- ceutically acceptable carrier is a non-naturally occurring pharma- ceutically acceptable carrier.

[0035] The terms "treat" and "treatment" refer to both therapeutic treatment and preventative or prophylactic measures, the purpose of which is to prevent or slow (lessen) the onset or spread of undesirable physiological changes or disorders, such as cancer. For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, whether detectable or undetectable, reduction in the extent of disease, a stable (i.e., not worsening) state of disease, a delay or slowing of disease progression, improvement or palliation of the disease state, and remission (partial or complete). "Treatment" can also mean prolonging survival compared to expected survival in the absence of treatment. Those in need of treatment include those already with a condition or disorder, as well as those prone to have the condition or disorder, or those in whom the condition or disorder is to be prevented.

[0036] The term "administration" or "administering" includes routes by which compounds are introduced into a subject to perform their intended function. Examples of routes of administration that may be used include injection (including but not limited to subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal), topical, oral, inhalation, rectal, and transdermal.

[0037] The term "effective amount" includes an amount effective at dosages and for periods of time necessary to achieve the desired result. The effective amount of a compound may vary depending on factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide an optimal therapeutic response.

[0038] The phrases "systemic administration," "administered systemically," "peripheral administration," and "administered peripherally," as used herein, refer to administration of a compound, drug, or other material such that it enters the patient's system and is thus subject to metabolic and other similar processes.

[0039] The phrase "therapeutically effective amount" refers to an amount of a compound of the present invention that (i) treats or prevents a particular disease, condition, or disorder, (ii) alleviates, improves, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein. In the case of cancer, a therapeutically effective amount of a drug may reduce the number of cancer cells, reduce the size of a tumor, inhibit (i.e., slow to some extent, and preferably stop) cancer cell invasion into peripheral organs, inhibit (i.e., slow to some extent, and preferably stop) tumor metastasis, inhibit tumor growth to some extent, and / or alleviate to some extent one or more symptoms associated with cancer. To the extent that a drug may prevent the growth and / or kill already existing cancer cells, the drug may be cytostatic and / or cytotoxic. In the case of cancer therapy, efficacy may be measured, for example, by assessing the time to disease progression (TTP) and / or determining the response rate (RR).

[0040] The term "subject" refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In certain embodiments, the subject is a human.

[0041] The present disclosure is directed to a fragment-based ligand discovery strategy suitable for identifying small molecules that bind to specific RNA regions with high affinity. In general, fragment-based ligand discovery allows for the identification of one or more small molecule "fragments" that bind to a target of interest with low to moderate affinity. These fragments are then either purified or ligated to create more potent ligands. 13、14 Typically, these fragments exhibit a molecular mass of less than 300 Da and make sufficient high-quality contacts with the target of interest to detectably bind.

[0042] Fragment-based ligand discovery has only been used successfully to identify initial hit compounds that are single fragment hits that bind to a given RNA. 15~19 Discrimination of multiple fragments that bind to the same RNA allows one to exploit potential additive and cooperative interactions between fragments within the binding pocket. 20、21 However, many RNAs have recently been shown to bind their ligands through multiple "subsites", which are regions of the binding pocket that contact the ligand in an independent or cooperative manner. 22 Furthermore, it has been shown that high affinity RNA binding can occur even when subsite binding exhibits only weak cooperativity effects. These features bode well for the efficacy of fragment-based ligand discovery development applied to RNA targets.

[0043] Thus, based on the above, the present disclosure is directed to a method for identifying fragments that bind to an RNA of interest, such as, for example, a TPP riboswitch. Second, the disclosed method is directed to establishing the location of fragment binding in the RNA with approximately nucleotide resolution. Third, the disclosed method is directed to identifying a second site fragment bound near the site of the initial fragment hit. The disclosed method combines a fragment-based ligand discovery approach with SHAPE-MaP RNA structural probing. 23、24 Both were used to identify the RNA-binding fragments and to establish the individual sites of fragment binding. The ligand finally created by linking the two fragments bears no similarity to natural riboswitch ligands and binds with high affinity to the structurally complex TPP riboswitch RNA.

[0044] The disclosed methods and the identification of ligands are described in more detail below.

[0045] A. Compound A first aspect of the subject matter of the present disclosure is a compound having a structure of formula (I): [ka] During the ceremony, X1, X2, and X3, in each occurrence, are independently selected from CR1, CHR1, N, NH, O, and S, and adjacent X1, X2, and X3 are not simultaneously selected to be O or S; The dashed line represents an optional double bond; Y1, Y2, and Y3, at each occurrence, are independently selected from CR2 and N; n is 1 or 2, and when n is 1, exactly one of the dashed lines is a double bond; L is [ka] wherein k, p, q, r, and v are independently selected from integers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; and z is selected from integers 1, 2, 3, 4, and 5; A is, [ka] is selected from wherein X4, X5, X6, and X7 are independently selected from CR3 and N; R1, R2, and R3 are independently selected from -H, -Cl, -Br, -I, -F, -CF3, -OH, -CN, -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -COOH, -COO(C1-C6 alkyl), -CO(C1-C6 alkyl), -O(C1-C6 alkyl), -OCO(C1-C6 alkyl), -NCO(C1-C6 alkyl), -CONH(C1-C6 alkyl), and substituted or unsubstituted C1-C6 alkyl; m is 1 or 2; W is -O or -NR4, where R4 is selected from -H, -CO(C1-C6 alkyl), substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, -CO(aryl), -CO(heteroaryl), and -CO(cycloalkyl); provided that at least two of X1, X2, X3, X4, X5, X6, and X7 are N; or a pharma- ceutically acceptable salt thereof.

[0046] As in any of the preceding embodiments, the compound wherein at least one of X1, X2, or X3 is N.

[0047] As in any of the preceding embodiments, the compound wherein X1 is N.

[0048] As in any of the preceding embodiments, the compound wherein X2 is N.

[0049] As in any of the preceding embodiments, the compound wherein X3 is N.

[0050] As in any of the preceding embodiments, compounds in which in each instance two of X1, X2, and X3 are N.

[0051] As in any of the preceding embodiments, the compound wherein X1 and X3 are N.

[0052] As in any of the above embodiments, the compound wherein at least one of Y1, Y2, and Y3 is N.

[0053] As in any of the preceding embodiments, the compound wherein Y1 is N.

[0054] As in any of the preceding embodiments, the compound wherein Y2 is N.

[0055] As in any of the preceding embodiments, the compound wherein Y3 is N.

[0056] As in any of the above embodiments, the compound wherein at least one of Y1, Y2, and Y3 is CR2.

[0057] As in any of the preceding embodiments, the compound wherein Y1 is CR2.

[0058] As in any of the preceding embodiments, the compound wherein Y2 is CR2.

[0059] As in any of the preceding embodiments, the compound wherein Y3 is CR2.

[0060] The compound as in any of the preceding embodiments, wherein n is 2.

[0061] As in any of the above embodiments, having the structure of formula (II): [ka] During the ceremony, X 2a and X 2b is independently selected from CR1 and N; X1 and X3 are independently selected from CR1 and N; L and A are as provided for formula (I); X1, X 2a , X 2b and two of X3 are N.

[0062] As in any of the above embodiments, having a structure of formula (III): [ka] During the ceremony, The compound, wherein L and A are as provided for formula (I).

[0063] As in any of the previous embodiments, the compound wherein p, q, r, and v are independently selected from the integers 0, 1, 2, and 3.

[0064] As in any of the above embodiments, L may be [ka] A compound selected from:

[0065] As in any of the above embodiments, L may be [ka] A compound.

[0066] As in any of the previous embodiments, the compound wherein q and r are 0 or 1.

[0067] The compound, as in any of the preceding embodiments, wherein q is 1.

[0068] The compound as in any of the preceding embodiments, wherein r is 1.

[0069] The compound as in any of the preceding embodiments, wherein r is 0.

[0070] The compound, as in any of the preceding embodiments, wherein q and r are 1.

[0071] The compound wherein q is 1 and r is 0, as in any of the preceding embodiments.

[0072] The compound as in any of the preceding embodiments, wherein m is 1.

[0073] As in any of the previous embodiments, the compound wherein W is selected from -NH, -O, and -N(C1-C6 alkyl)2.

[0074] The compound wherein W is -NH, as in any of the preceding embodiments.

[0075] As in any of the preceding embodiments, the compound wherein at least one of X4, X5, X6, and X7 is N.

[0076] As in any of the preceding embodiments, the compound wherein X4 is N.

[0077] As in any of the preceding embodiments, the compound wherein X5 is N.

[0078] As in any of the preceding embodiments, the compound wherein X6 is N.

[0079] As in any of the preceding embodiments, the compound wherein X7 is N.

[0080] As in any of the preceding embodiments, the compound wherein X4 and X6 are N.

[0081] As in any of the preceding embodiments, the compound wherein X5 and X7 are N.

[0082] As in any of the preceding embodiments, compounds wherein X5 or X6 is N, and both X4 and X7 are independently CR2.

[0083] As in any of the above embodiments, A may be [ka] A compound.

[0084] As in any of the above embodiments, the structure [ka] A compound having the formula:

[0085] As in any of the above embodiments, L may be [ka] A compound.

[0086] As in any of the above embodiments, compounds in which Y1, Y2, and Y3, at each occurrence, are independently selected from CR2 and N, and R1 is selected from -H, -Cl, -Br, -I, -F, -OH, and -NH2.

[0087] The compound, as in any of the preceding embodiments, wherein z is 2.

[0088] As in any of the preceding embodiments, the compound wherein Y2 is N.

[0089] As in any of the above embodiments, the compound wherein Y2 is CR2 and R1 is selected from -H, -F, -OH, and -NH2.

[0090] As in any of the above embodiments, A may be [ka] A compound.

[0091] As in any of the above embodiments, the compound has the structure: [ka] A compound having the formula:

[0092] As in any of the above embodiments, the compound has the structure: [ka] A compound having the formula:

[0093] B. Screening Methods The present disclosure is directed to the development and validation of a flexible selective 2'-hydroxyl acylation assayed by primer extension (SHAPE)-based fragment screening method. Fragment-based ligand discovery has proven to be an effective approach for identifying compounds that form substantially intimate contacts with macromolecules, including RNA. 13、14、17 A prerequisite for the success of this discovery strategy is an adaptable, high-quality biophysical assay to detect ligand binding. Thus, in some embodiments, SHAPE RNA structural probing is utilized to detect ligand binding. 23~25, which measures local nucleotide flexibility as the relative reactivity of the ribose 2'-hydroxyl group towards electrophiles. SHAPE can be used on any RNA, providing data for virtually every nucleotide in an RNA in a single experiment, and obtaining structural information per nucleotide in addition to simply detecting binding, as described in more detail below. In addition, the present disclosure is also directed to applying SHAPE mutational profiling (MaP). 23、24 SHAPE combines with high-throughput sequencing readout to enable multiplexing and efficient high-throughput analysis of thousands of samples.

[0094] Thus, in some embodiments, the present disclosure is directed to screening methods that utilize SHAPE and / or SHAPE-MaP to identify small molecule fragments and / or compounds that bind to and / or associate with an RNA molecule of interest. The methods disclosed herein further include utilizing SHAPE and / or SHAPE-MaP to identify small molecule fragments (e.g., fragment 2) that bind to and / or associate with an RNA molecule that has already been pre-incubated with another small molecule fragment (e.g., fragment 1). Without wishing to be bound by theory, it is believed that fragment 1 binds to a first binding site and fragment 2 binds to a second binding site (e.g., subsite) in the same RNA molecule. Thus, it is believed that combining the structural features of fragment 1 and fragment 2 (e.g., connecting the two fragments with a linker L) to generate the compounds disclosed herein results in linked fragment ligands with increased RNA binding affinity compared to fragment 1 and / or fragment 2 alone.

[0095] The screening methods SHAPE and SHAPE-MaP are described in more detail below.

[0096] I. SHAPE Chemistry SHAPE chemistry is based, at least in part, on the observation that the nucleophilicity of the 2' position of the RNA ribose is sensitive to the electronic influence of the adjacent 3'-phosphodiester group. Unconstrained nucleotides sample more conformations that enhance the nucleophilicity of the 2'-hydroxyl group than base-paired or otherwise constrained nucleotides. Thus, hydroxyl-selective electrophiles (such as, but not limited to, N-methylisatoic anhydride (NMIA)) more rapidly form stable 2'-O adducts with flexible RNA nucleotides. Local nucleotide flexibility can be examined simultaneously at all positions in an RNA molecule in a single experiment because all RNA nucleotides (except some cellular RNAs with post-transcriptional modifications) have a 2'-hydroxyl group. Because 2'-hydroxyl reactivity is insensitive to base identity, absolute SHAPE reactivity can be compared across all positions in an RNA. It is also possible that a nucleotide can be reactive because it is constrained into a conformation that enhances the nucleophilicity of a particular 2'-hydroxyl. This type of nucleotide is expected to be rare, has a non-canonical local geometry, and would be correctly scored as an unpaired position.

[0097] The subject matter of the present disclosure, in some embodiments, provides a method for detecting structural data in RNA molecules by examining structural constraints in RNA molecules of any length and structural complexity. In some embodiments, the method includes annealing RNA molecules containing 2'-O-adducts with a (labeled) primer, annealing RNA molecules not containing 2'-O-adducts with a (labeled) primer as a negative control, extending the primer to generate a library of cDNA, analyzing the cDNA, and generating an output file that includes structural data for the RNA.

[0098] The RNA molecule may be present in a biological sample. In some embodiments, the RNA molecule may be modified in the presence of proteins or other small and large biological ligands and / or compounds. The primer may be optionally labeled with a radioisotope, a fluorescent label, a heavy atom, an enzyme label, a chemiluminescent group, a biotinyl group, a predetermined polypeptide epitope recognized by a secondary reporter, or a combination thereof. Analyzing may include separating, quantifying, sizing, or a combination thereof. Analyzing may include extracting fluorescence or dye amount data as a function of elution time data, called a trace. As an example, cDNA may be analyzed in a single-column capillary electrophoresis instrument or in a microfluidic device.

[0099] In some embodiments, the peak area of ​​the trace for the RNA molecules containing 2'-O-adducts and the RNA molecules not containing 2'-O-adducts against the nucleotide sequence can be calculated. The trace can be compared and aligned with the sequence of the RNA. The trace that observes and describes these cDNAs generated by sequencing is one nucleotide longer than the corresponding position in the trace for the RNA molecules containing 2'-O-adducts and the RNA molecules not containing 2'-O-adducts. The area under each peak can be determined by performing a Gaussian fit integration of the entire trace.

[0100] Thus, in some embodiments, provided herein are methods for forming covalent ribose 2'-O-adducts with RNA molecules in complex biological solutions. In some embodiments, the methods include contacting the RNA molecules with an electrophile, where the electrophile selectively modifies unconstrained nucleotides in the RNA molecule to form covalent ribose 1'-O-adducts.

[0101] In some embodiments, an electrophile, such as, but not limited to, N-methylisatoic anhydride (NMIA), is dissolved in an anhydrous polar aprotic solvent, such as DMSO. The reagent-solvent solution is added to a complex biological solution containing RNA molecules. The solution may contain different concentrations and amounts of proteins, cells, viruses, lipids, mono- and polysaccharides, amino acids, nucleotides, DNA, as well as different salts and metabolites. The concentration of the electrophile can be adjusted to achieve the desired degree of modification in the RNA molecule. The electrophile has the potential to react with all free hydroxyl groups in the solution, producing ribose 2'-O-adducts on the RNA molecule. Furthermore, the electrophile can selectively modify unpaired or otherwise unconstrained nucleotides in the RNA molecule.

[0102] RNA molecules can be exposed to electrophiles at concentrations that result in fewer RNA modifications forming 2'-O-adducts, which can be detected by their ability to inhibit primer extension by reverse transcriptase. Because this chemistry targets the general reactivity of 2'-hydroxyl groups, all RNA sites can be examined in a single experiment. In some embodiments, control extension reactions omitting the electrophile to assess background, and dideoxy sequencing extensions to assign nucleotide positions can be performed in parallel. These combined steps are referred to as primer extension, or selective 2'-hydroxyl acylation, analyzed by SHAPE.

[0103] In some embodiments, the method further comprises contacting the RNA molecules containing 1'-O-adducts with a (labeled) primer, contacting an RNA molecule not containing a 2'-O-adduct with the (labeled) primer as a negative control, extending the primer to generate a linear array of cDNA, analyzing the cDNA, and generating an output file comprising RNA structural data.

[0104] The number of nucleotides interrogated in a single SHAPE experiment depends on the nature of the RNA modification as well as the detection and resolution of the separation technique used. Considering the reaction conditions, there are lengths at which nearly all RNA molecules have at least one modification. When primer extension reaches these lengths, the amount of cDNA extended decreases, attenuating the experimental signal. Adjusting conditions to reduce the modification yield can increase the read length. However, lowering the reagent yield can also decrease the measured signal for each cDNA length. Taking these considerations into account, the preferred maximum length of a single SHAPE read is probably about 1 kilobase of RNA, but should not be limited to this.

[0105] II.SHAPE-Map In SHAPE-MaP, SHAPE adducts are detected by mutation profiling (MaP), which exploits the ability of reverse transcriptase to incorporate non-complementary nucleotides or generate deletions at the site of the SHAPE chemical adduct. In some embodiments, SHAPE-MaP can be used for library construction and sequencing. In some embodiments, multiplexing techniques can be used for SHAPE-MaP.

[0106] Typically, RNA is treated with SHAPE reagents that react with conformationally dynamic nucleotides. During reverse transcription, the polymerase reads through the chemical adducts in the RNA and incorporates nucleotides non-complementary to the original sequence into the cDNA. The resulting cDNA is sequenced using any massively parallel approach to create a mutation profile (MaP). Sequencing reads are aligned to a reference sequence, nucleotide resolution mutation rates are calculated, corrected for background, normalized, and a standard SHAPE reactivity profile is generated. SHAPE reactivity can then be used to model secondary structures, visualize competing and alternative structures, or quantify any process or function that regulates local nucleotide RNA dynamics. After SHAPE modification of the RNA molecule, reverse transcriptase is used to create a mutation profile. This step encodes the location and relative frequency of the SHAPE adducts as mutations in the cDNA. Using methods known in the art (e.g., PCR reactions), the cDNA is converted to dsDNA, which is further amplified in a second PCR reaction, thereby adding sequencing for multiplexing. After purification, the sequencing library has a uniform size, with each DNA molecule containing the entire sequence of interest.

[0107] Thus, according to some embodiments of the subject matter of the present disclosure, a method for detecting one or more chemical modifications in a nucleic acid is provided. In some embodiments, the method includes providing a nucleic acid suspected of having a chemical modification, synthesizing a nucleic acid using a polymerase and the provided nucleic acid as a template, where the synthesizing occurs under conditions in which the polymerase reads through the chemical modification in the provided nucleic acid, thereby producing an incorrect nucleotide in the resulting nucleic acid at the site of the chemical modification, and detecting the incorrect nucleotide.

[0108] According to some embodiments of the presently disclosed subject matter, a method for detecting structural data in a nucleic acid is provided. In some embodiments, the method includes providing a nucleic acid suspected of having a chemical modification, synthesizing a nucleic acid using a polymerase and the provided nucleic acid as a template, where the synthesizing occurs under conditions where the polymerase reads through the chemical modification in the provided nucleic acid, thereby producing an incorrect nucleotide in the resulting nucleic acid at the site of the chemical modification, detecting the incorrect nucleotide, and generating an output file that includes structural data for the provided nucleic acid.

[0109] In some embodiments of the presently disclosed subject matter, the provided nucleic acid is an RNA molecule (e.g., a coding and / or a non-coding RNA molecule). In some embodiments, the method comprises detecting two or more chemical modifications. In some embodiments, the polymerase reads through multiple chemical modifications to produce multiple incorrect nucleotides, and the method comprises detecting each of the incorrect nucleotides.

[0110] In some embodiments, the nucleic acid (e.g., RNA molecule) is exposed to a reagent that provides a chemical modification, or the chemical modification is already present in the nucleic acid (e.g., RNA molecule). In some embodiments, the already present modification is a 2'-O-methyl group and / or is created by the cell from which the nucleic acid is derived, such as, but not limited to, epigenetic modifications and / or modifications 1-methyladenosine, 3-methylcytosine, 6-methyladenosine, 3-methyluridine, and / or 2-methylguanosine. In some embodiments, nucleic acids such as RNA molecules can be modified in the presence of proteins or other small and large biological ligands and / or compounds.

[0111] In some embodiments, the reagent comprises an electrophile. In some embodiments, the electrophile selectively modifies unconstrained nucleotides in an RNA molecule to form covalently linked ribose 2'-O-adducts. In some embodiments, the reagent is 1 M7, 1 M6, NMIA, DMS, or a combination thereof. In some embodiments, the nucleic acid is present in or derived from a biological sample.

[0112] In some embodiments, the polymerase is a reverse transcriptase. In some embodiments, the polymerase is a native or mutant polymerase. In some embodiments, the synthetic nucleic acid is a cDNA.

[0113] In some embodiments, detecting the incorrect nucleotide comprises sequencing the nucleic acid. In some embodiments, the sequence information is aligned with the sequence of the provided nucleic acid. In some embodiments, detecting the incorrect nucleotide comprises using massively parallel sequencing on the nucleic acid. In some embodiments, the method comprises amplifying the nucleic acid. In some embodiments, the method comprises amplifying the nucleic acid using a site-specific approach using specific primers, whole genome using random priming, whole transcriptome using random priming, or a combination thereof.

[0114] According to some embodiments of the presently disclosed subject matter, there is provided a computer program product comprising computer executable instructions embodied in a computer readable medium for performing steps including any method steps of any embodiment of the presently disclosed subject matter. According to some embodiments of the presently disclosed subject matter, there is provided a nucleic acid library generated by any method of the presently disclosed subject matter.

[0115] III. SHAPE Electrophiles As disclosed herein above, SHAPE chemistry takes advantage of the discovery that the nucleophilic reactivity of the ribose 2'-hydroxyl group is gated by local nucleotide flexibility. In nucleotides that are constrained by base pairing or tertiary interactions, the 3'-phosphodiester anion and other interactions reduce the reactivity of the 2'-hydroxyl. In contrast, flexible positions preferentially adopt conformations that react with electrophiles (including but not limited to NMIA) to form 2'-O-adducts. As an example, NMIA generally reacts with all four nucleotides, and the reagent undergoes parallel self-inactivating hydrolysis reactions. Indeed, the presently disclosed subject matter provides that any molecule capable of reacting with the nucleic acids disclosed herein can be used in accordance with some embodiments of the presently disclosed subject matter. In some embodiments, the electrophile (also referred to as the SHAPE reagent) can be selected from, but not limited to, isatoic anhydride derivatives, benzoyl cyanide derivatives, benzoyl chloride derivatives, phthalic anhydride derivatives, benzyl isocyanate derivatives, and combinations thereof. The isatoic anhydride derivative may include 1-methyl-7-nitroisatoic anhydride (1M7). The benzoyl cyanide derivative may be selected from the group including, but not limited to, benzoyl cyanide (BC), 3-carboxybenzoyl cyanide (3-CBC), 4-carboxybenzoyl cyanide (4-CBC), 3-aminomethylbenzoyl cyanide (3-AMBC), 4-aminomethylbenzoyl cyanide, and combinations thereof. The benzoyl chloride derivative may include benzoyl chloride (BCl). The phthalic anhydride derivative may include 4-nitrophthalic anhydride (4NPA). The benzyl isocyanate derivative may include benzyl isocyanate (BIC).

[0116] IV.RNA molecule design Because SHAPE reactivity can be assessed in one or more primer extension reactions, information can be lost both at the 5' end of the RNA molecule and near the primer binding site. Typically, adduct formation at 10-20 nucleotides adjacent to the primer binding site is difficult to quantitate due to the presence of cDNA fragments reflecting stalling or non-templated extension by the reverse transcriptase (RT) enzyme during the initial stages of primer extension. Positions 8-10 at the 5' end of the RNA can be difficult to visualize due to the presence of abundant full-length extension products.

[0117] To monitor SHAPE reactivity at the 5' and 3' ends of a sequence of interest, the RNA molecule can be embedded within a larger fragment of the native sequence or placed between tightly folded RNA sequences that contain unique primer binding sites. In some embodiments, structural cassettes containing 5' and 3' flanking sequences of nucleotides can be designed to allow for evaluation of all positions within the RNA molecule of interest with any separation technique that provides nucleotide resolution, such as, but not limited to, sequencing gels, capillary electrophoresis, etc. In some embodiments, both the 5' and 3' extensions can be folded into stable hairpin structures that do not interfere with the folding of various internal RNAs. The primer binding sites of the cassettes can efficiently bind to cDNA primers. The sequences of any 5' and 3' structural cassette elements can be examined to ensure that they are unlikely to form stable base pair interactions with internal sequences.

[0118] In some embodiments, the RNA molecule of interest comprises two different target motifs connected with a nucleotide linker. The target motif can be any nucleotide sequence of interest. Exemplary target motifs include, but are not limited to, riboswitches, viral regulatory elements, structured regions in mRNA, multiple helix junctions, pseudoknots and / or aptamers. In some embodiments, the first target motif is a pseudoknot, e.g., a pseudoknot from the 5'UTR of the dengue virus genome. In some embodiments, the second target motif is an aptamer domain, e.g., a TPP riboswitch aptamer domain. For nucleotide linkers, the number of nucleotides can vary. For example, in some embodiments, the number of nucleotides in the linker ranges from about 1 to about 20 nucleotides, about 1 to about 15 nucleotides, about 1 to about 10 nucleotides, or about 5 to about 10 nucleotides (or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides).

[0119] In some embodiments, the RNA molecule further comprises an RNA barcode region. The RNA barcode region is a unique barcode that allows for the identification of a particular RNA molecule in a mixture of RNA molecules (e.g., during multiplexing). The location of the RNA barcode region may vary, but is typically found adjacent to one of the cassettes present in the RNA molecule. In some embodiments, the RNA barcode is designed to fold into a self-containing structure that does not interact with any other portion of the RNA molecule. The structure of the RNA barcode region may vary. In some embodiments, the structure of the RNA barcode region comprises a base-paired helix comprising about 1 to about 10 base pairs (or about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 base pairs). In some embodiments, the RNA barcode region comprises 7 base pairs. In some embodiments, the base pairs are capped with a tetraloop fixed to the terminal base pair of the base-paired helix. Capping the base-paired helix maintains the overall hairpin stability of the RNA barcode region. In some embodiments, the tetraloop comprises, but is not limited to, the nucleotide sequence GNRA. In some embodiments, the RNA barcode region is designed such that any individual barcode is subject to at least two mutations that would be misinterpreted as a separate barcode.

[0120] V. Folding of RNA molecules The subject matter of the present disclosure may be implemented with RNA molecules produced by methods including, but not limited to, in vitro transcription, as well as RNA molecules produced in cells and viruses. In some embodiments, the RNA molecules may be purified by denaturing gel electrophoresis and renatured to achieve biologically relevant conformations. Additionally, any procedure that folds the RNA molecule into a desired conformation at a desired pH (e.g., about pH 8) may be substituted. First, the RNA molecule may be heated and rapidly cooled in a low ionic strength buffer to eliminate multimeric forms. A folding solution may then be added to allow the RNA molecule to achieve the appropriate conformation and prepare it for structure-sensitive probing with electrophiles. In some embodiments, the RNA may be folded in a single reaction and then separated into (+) and (-) electrophile reactions. In some embodiments, the RNA molecule does not naturally fold before modification. Modification may be performed while the RNA molecule is denatured by heat and / or low salt conditions.

[0121] VI.RNA molecule modification Electrophiles can be added to RNA to obtain 2'-O-adducts at flexible nucleotide positions. The reaction can then be incubated until essentially all of the electrophiles have reacted with the RNA or decomposed due to hydrolysis by water. No specific quenching step is required. The modification can be performed in the presence of complex ligands and biomolecules, as well as in the presence of various salts. RNA may be modified in cells and viruses as well. These salts and complex ligands can include magnesium, sodium, manganese, iron, and / or cobalt salts. Complex ligands can include, but are not limited to, proteins, lipids, other RNA molecules, DNA, or small organic molecules. In some embodiments, the complex ligand is a small molecule fragment disclosed herein. In some embodiments, the complex ligand is a compound disclosed herein. The modified RNA can be purified from reaction products and buffer components that may be detrimental to the primer extension reaction, for example, by ethanol precipitation.

[0122] VII. Primer Extension and Polymerization Analysis of RNA adducts by primer extension according to the subject matter of the present disclosure may, in various embodiments, include the use of optimized primer binding sites, thermostable reverse transcriptase, low MgCl2 concentration, high temperature, short extension time, and any combination of the above. Intact, undegraded RNA, free of reaction by-products and other small molecule contaminants, can also be used as a template for reverse transcription. The RNA component of the resulting RNA-cDNA hybrid can be degraded by treatment with base. The cDNA fragments can then be separated using, for example, polyacrylamide sequencing gels, capillary electrophoresis, or other separation techniques that will become apparent to those skilled in the art after reviewing this disclosure.

[0123] Deoxyribonucleotide triphosphates dATP, dCTP, dGTP, and dTTP and / or deoxyribonucleotide triphosphates (dNTPs) can be added to the synthesis mixture in sufficient amounts, either separately or together with the primers, and the resulting solution can be heated to about 50-100°C for about 1-10 minutes. After the heating period, the solution can be cooled. In some embodiments, an appropriate agent for effecting a primer extension reaction can be added to the cooled mixture and the reaction can occur under conditions known in the art. In some embodiments, an agent for polymerization can be added along with other reagents if it is thermostable. In some embodiments, the synthesis (or amplification) reaction can occur at room temperature. In some embodiments, the synthesis (or amplification) reaction can occur up to a temperature at which the agent for polymerization is no longer functional.

[0124] The agent for polymerization can be any compound or system that functions to achieve the synthesis of primer extension products, including, for example, enzymes. Suitable enzymes for this purpose include, but are not limited to, E. coli DNA polymerase I, the Klenow fragment of E. coli DNA polymerase, polymerase muteins, reverse transcriptase, and other enzymes, including thermostable enzymes (i.e., enzymes that undergo primer extension after exposure to a temperature high enough to cause denaturation), such as mouse or avian reverse transcriptase. Suitable enzymes can facilitate the combination of nucleotides in the appropriate manner to form primer extension products complementary to each polymorphic locus nucleic acid strand. In some embodiments, synthesis can begin at the 5' end of each primer and proceed in the 3' direction until synthesis terminates at the end of the template, generating molecules of different lengths by incorporation of dideoxynucleotide triphosphates or with 2'-O-adducts.

[0125] The newly synthesized strand and its complementary nucleic acid strand can form a double-stranded molecule under hybridization conditions described herein, and this hybrid can be used in a subsequent step, such as in the disclosed methods described in U.S. Patent Nos. 10,240,188 and 8,318,424, which are incorporated herein by reference in their entireties. In some embodiments, the newly synthesized double-stranded molecule can also be subjected to denaturing conditions using any of the procedures known in the art to provide single-stranded molecules.

[0126] VII. Raw Data Processing The subject matter described herein for nucleic acid, such as RNA molecules, chemical modification analysis, and / or nucleic acid structure analysis, can be implemented using a computer program product that includes computer executable instructions embodied in a computer readable medium. Exemplary computer readable media suitable for implementing the subject matter described herein include chip memory devices, disk memory devices, programmable logic devices, and application specific integrated circuits. In addition, the computer program product that implements the subject matter described herein can be located on a single device or computing platform, or can be distributed across multiple devices or computing platforms. Thus, the subject matter described herein can include a set of computer instructions that, when executed by a computer, performs a specific function for nucleic acid, such as RNA structure analysis.

[0127] Taking into account items I-VII above, a modular RNA screening construct was designed to implement SHAPE as a high-throughput assay for readout of ligand binding (Figure 1, top). The construct incorporates a pseudoknot from the 5'UTR of the dengue virus genome, which reduces viral fitness when its structure is disrupted. 26 , and the TPP riboswitch aptamer domain 27~29 The construct was designed to contain two target motifs, such as the structural motif α, β, and β. The inclusion of two different structural motifs in a single construct allowed each to act as an internal specificity control for the other. Fragments that bound to both RNA structures were easily identified as non-specific binders. These two structures were connected by a 6-nucleotide linker that was designed to be single-stranded, allowing the two RNA structures to remain structurally independent. Adjacent to the structural core of the construct was a structural cassette 25 These stem-loop forming regions were used as primer binding sites for required steps in the screening workflow and were designed not to interact with other structures in the construct (Figure 7).

[0128] Another component of the screening construct is the RNA barcode, which allows for multiplexing that substantially reduces downstream workload. Each well in the 96-well plate used to screen the fragment library contains RNA with a unique barcode in terms of the otherwise identical construct, and thus the barcode sequence identifies the well location and the fragment (or fragments) present after multiplexing (Figure 1). The RNA barcode region was designed to fold into a self-containing structure that does not interact with any other part of the construct. The barcode structure is a seven-base pair helix capped with a GNRA tetraloop and anchored with GC base pairs to maintain hairpin stability (Figure 7). Each set of 96 barcodes was designed to suffer from two or more mutations that would cause any individual barcode to be misinterpreted as another barcode.

[0129] This construct provides flexibility in choosing RNA structures to screen for ligand binding and aids in simple, straightforward screening experiments (Figure 1). Each well in a 96-well plate containing an otherwise identical RNA construct with a unique RNA barcode is incubated with one or a few small molecule fragments or a no-fragment control (solvent) and then exposed to SHAPE reagents. The resulting SHAPE adducts chemically encode structural information per nucleotide. After SHAPE probing, the RNA from the 96 wells of the plate can be pooled into a single sample because the information required to determine fragment identity (RNA barcode) and fragment binding (SHAPE adduct pattern) is permanently encoded on each RNA strand. Fragment screening experiments follow the standard MaP structural probing workflow. 24 For example, in some embodiments, a specialized relaxed fidelity reverse transcription reaction is used to generate cDNA containing changes in the non-template coding sequence at the location of any SHAPE adducts on the RNA. 30These cDNAs are then used to prepare DNA libraries for high-throughput sequencing. Multiple plates of an experiment are barcoded at the DNA library level. 24 , data on thousands of compounds can be collected in a single sequencing run (Figure 1). The resulting sequencing data contains millions of individual reads, each corresponding to a specific RNA strand. These reads are sorted by barcode, allowing analysis of the data for each small molecule fragment or combination of fragments. Determination and identification of small molecule fragments (e.g., fragment 1 and / or fragment 2) using the methods described above, such as SHAPE and / or SHAPE-MaP, is described in more detail in the next section.

[0130] C. Ligand Identification and Selection As described above, SHAPE and SHAPE-MaP were used to identify small molecule fragments that bind or associate with an RNA molecule of interest. In particular, when using SHAPE-MaP to test small molecule fragments, detection of bound fragment signatures from SHAPE-MaP mutation rates per nucleotide involves multiple steps to normalize data across large experimental screens and ensure statistical rigor. The key features of the SHAPE-based hit analysis strategy involve (i) comparing the RNAs exposed to each fragment, or "experimental samples," with five negative fragment-unexposed control samples to account for plate-to-plate and well-to-well variability, (ii) hit detection performed independently for each of the two structural motifs in the construct, in this disclosure the pseudoknot and the TPP riboswitch, (iii) masking of individual nucleotides with low reactivity across all samples, as they are unlikely to show fragment-induced changes, and (iv) calculation of the per-nucleotide difference in mutation rates between the fragment-exposed experimental samples and the fragment-unexposed negative control samples. For Z-score analysis, those nucleotides with a mutation rate difference of 20% or more between one of the motifs and a control without the fragment were selected. However, one skilled in the art would recognize that the mutation rate difference may vary and would be able to adjust the mutation rate difference accordingly. For example, in some embodiments, the mutation rate difference may be 25%, 30%, 35%, 45%, or 50%, or more. In some embodiments, the mutation rate difference may be 15%, 10%, or 5%, or more. Three or more nucleotides in one of the two motifs have a Z value greater than 2.7 (comparison of Poisson numbers for the two motifs). 31It was determined that the fragment significantly altered the SHAPE reactivity pattern if the Z value was greater than 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, or 3.9. In some embodiments, the Z value is greater than 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, or 2.6.

[0131] A series of steps are carried out to identify small molecule fragments with SHAPE and / or SHAPE-MaP that are subsequently linked together to generate the compounds disclosed herein. First, a primary screening is carried out to screen a large number of compounds (e.g., at least 100 compounds) to identify any initial lead or hit compounds that exhibit suitable binding activity to the target RNA molecule. In step 2, these hit compounds are then further examined in structure-activity relationship (SAR) studies to determine the change in binding affinity of the target RNA as the structure of the hit compound is modified. If multiple small molecule fragments are identified as suitable binding ligands for the target RNA molecule, additional binding studies may be carried out to further examine the binding site for each small molecule fragment (i.e., step 3). For example, in some embodiments, after pre-incubating the target RNA with a first fragment (identified as a target RNA binding ligand according to the SAR study in step 2), the target RNA can be exposed to a second fragment (also identified as an RNA binding ligand in the SAR study in step 2) to identify whether the second fragment can bind to the target RNA when the first fragment is already bound. Once a second fragment with suitable binding activity for the RNA of interest has been identified, the second fragment can be linked to the first fragment using a linker to form a compound as disclosed herein (i.e., step 4). Each of the above steps is described in more detail below.

[0132] Step 1: Primary screening In the primary screen, 1,500 fragments were tested and 41 fragments were detected as hits, giving an initial hit rate of 2.7%. Hit validation was performed by SHAPE analysis of three replicates (Figure 2, Figure 8), and a compound was accepted as a true hit only if it was detected as a binder in all three replicates. The hit compounds of these replicates were then analyzed by isothermal titration calorimetry (ITC) to determine their binding affinity to an RNA that just corresponds to the target motif (omitting the flanking sequences in the screening construct). Of these initial hits, eight hits were validated by replicate analysis and ITC (Table 1). Seven of the hits bound to the TPP riboswitch based on their mutation signatures that were mostly or completely localized within the TPP riboswitch region of the test construct. The remaining hit was nonspecific because the fragment affected nucleotides throughout all parts of the RNA construct. No compounds were detected that specifically bound to the dengue pseudoknot region of the test construct. [Table 1]

[0133] Hits were detected by SHAPE structural probing and validated by replicate analysis and ITC. Dissociation constants were determined by ITC, error values ​​marked with ‡ indicate standard errors derived from ≥3 replicates, other error estimates are calculated based on 95% confidence intervals of least-squares regression of binding curves. For comparison, the native TPP ligand is included.

[0134] As verified by ITC, the seven fragments bound to the TPP riboswitch have diverse chemical types, with most fragments having little or no similarity to the natural TPP ligands (Table 1). Overall, heteroaromatic nitrogen-containing rings predominate, which are likely involved in hydrogen-bonding interactions. Three compounds have a pyridine ring and two have a pyrazine ring. An azole ring moiety is present in three compounds, two thiadiazoles and one imidazole. Although a thiazole ring is present in the natural TPP ligands, this moiety is not involved in binding interactions with RNA. 28、29、33 In addition, a number of the identified fragments contain primary amines, esters and ethers, as well as fluorine groups that can function as hydrogen bond acceptors or donors.

[0135] Step 2: Structure-activity relationship (SAR) of the riboswitch-binding fragment Next, several analogs of the initial hits were examined with the goal of increasing binding affinity and identifying positions where the fragment hits could be modified with linkers without interfering with binding. In particular, analogs of compounds 2 and 5 were considered because these two fragments are structurally distinct and analogs are commercially available. Analog-RNA binding was assessed by ITC. Sixteen analogs of 2 were tested. Altering the core quinoxaline structure of 2 by removing one or both ring nitrogens altered the binding activity (Table 2A). [Table 2A]

[0136] Modifications to the quinoxaline core were examined and dissociation constants were obtained by ITC.

[0137] Improvements in binding affinity were brought about by the introduction of methylene-linked hydrogen bond acceptors or donors (Table 2B, compounds 16 and 17). Varying the substituents at other positions on the quinoxaline ring core reduced binding activity. Compound 2 was a good candidate for further development based on the high degree of flexibility and further improvement in binding observed upon modification of the substituent at the C-6 position. [Table 2B]

[0138] Next, 18 analogs of fragment 5 were examined, suggesting that the core pyridine functionality of the molecule appears to be important for binding, as altering the ring nitrogen position, adding or removing a ring nitrogen all reduced or abolished binding (Table 3). [Table 3]

[0139] Modifications to the ring substituents generally significantly abolished binding activity (Table 4). The only affinity-increasing analog featured a chlorine at the C-4 position (S12), resulting in a compound with approximately 3-fold higher affinity for the TPP riboswitch than fragment 5. [Table 4]

[0140] Step 3: Identifying the fragment that binds to a second site on the TPP riboswitch A second round of screening was used to identify fragments that bound to the TPP riboswitch region of screening constructs that were pre-bound to compounds 2 or S12. This screen identified fragments that preferentially interacted with the TPP riboswitch when 2 or S12 were already bound, either due to cooperativity effects or because new modes of binding became available due to conformational changes that occurred upon primary ligand binding (Figure 3). Of the 1,500 fragments screened, five were verified to bind simultaneously with either 2 or S12 (Table 5). [Table 5]

[0141] One secondary screening hit, 29, induced very stable changes in the SHAPE reactivity signal and appeared to cause considerable changes in RNA structure, including unfolding of the P1 helix. Because this fragment caused changes in other regions of the RNA consistent with nonspecific interactions, this fragment was not considered further as a candidate for fragment ligation. Fragment 28 was insoluble at the concentrations required for ITC analysis, so related analogs containing a pyridine instead of a quinoline ring were examined by ITC (Table 6). These compounds bound with weak affinity, but nevertheless, 31 and 32 showed clear but weak binding cooperativity with 2. [Table 6] * und (not determined), insoluble, compound insoluble at the concentrations required for ITC, due to inability to fit ITC binding curves. [Table 7-1] [Table 7-2]

[0142] Step 4: Cooperativity and Fragment Linking The cooperative binding interaction between 2 and 31 was quantified by ITC. Individually, 2 has a K d 31 binds at a much higher K of 10 mM d Similar to the secondary screen, the affinity of fragment 31 was also examined when 2 was prebound to the TPP riboswitch RNA and formed a 2-RNA complex. Under these conditions, fragment 31 bound with a K of approximately 3 mM. d 31 bound to the 2-TPP RNA complex at 37C (Figure 4). This experiment also showed that 31 bound to the TPP RNA when binding by 2 was saturated, implying that the two fragments do not bind to the same location. Because 2 and 31 bound with good and reasonable affinity to different regions of the TPP RNA, the two fragments were ligated with the aim of creating a high affinity ligand.

[0143] Based on the SAR analysis of fragment hits 2 (Table 2B) and 28 (Table 4), linked analogs of the most promising SAR fragments were prepared, focusing on the aminomethyl position of 17 and two sites in the pyridine ring of fragment 31 (Figure 5). First, the affinities of the fragments conjugated with amide or amine linkers were compared. The compound with a flexible amine linker (compound 36) had a five-fold higher binding affinity than the amine-linked version (compound 35, Figure 5). These linkages were designed to be similar to those that occur at the pyrophosphate moiety of the natural TPP ligand. 27、28 , introduced in the context of hydroxamic acids capable of chelating magnesium ions. 35However, the amine-linked hydroxamic acid compound 36 bound with a similar affinity as the parent fragment 17, suggesting that the hydroxamic acid moiety does not confer additional binding affinity by chelating ions. Linked compound 37 bound with an affinity of 625 nM, indicating that, to the right approximation, linking two fragments of weak affinity can achieve higher nanomolar binders. Replacing the fragment 31 entity with a tertiary amine (compound 38) reduced the affinity compared to compound 37, suggesting that the interaction of fragment 31 with RNA is mediated by more than just charge-driven effects. Finally, varying the length of the link between the 17 and 31 moieties (compound 39) or by a pyridine ring linkage site (compound 40) reduced the affinity compared to compound 37 (Figure 5). Finally, the individually bound compounds were linked to the TPP riboswitch with affinities of 5.0 μM (compound 19) and >10 mM (compound 31), resulting in a K of 625 nM. d We created a compound (37) that binds to RNA.

[0144] Those skilled in the art will appreciate that the above steps I-IV are not meant to be limiting, but merely serve as exemplary embodiments. Those skilled in the art will appreciate that the above steps I-IV can be applied to identify alternative fragments that can be linked together to form compounds disclosed herein that have suitable binding affinity to TPP riboswitches. Furthermore, those skilled in the art will appreciate that the above steps I-IV can be applied to identify fragments that can be linked together to form compounds disclosed herein that bind to other RNA molecules of interest.

[0145] D. Summary and Additional Considerations Because both coding (mRNA) and non-coding RNAs can potentially be manipulated to alter cellular regulation and the course of disease, there was a need to develop an efficient strategy to identify small molecule ligands of structured RNA. The work disclosed herein demonstrates the promise of using a fragment-based strategy and a SHAPE screening readout to detect ligand binding to fused RNA. Here, using this strategy, we have identified a K d We generated ligands that bind to TPP riboswitches that are structurally unrelated to the natural ligands. The combined SHAPE and fragment-based screening approach is general to both the RNA structures that can be targeted and the ligand chemistries that can be developed. This strategy is well suited to discovering ligands for RNAs with complex structures, which may be essential for identifying RNA motifs that bind in three-dimensional pockets. 4 In addition, due to the use of the MaP approach and the application of multiplexing with both RNA and DNA barcoding, the effort required to screen a fragment library of over 1000 members is modest, allowing for the efficient screening of many structurally diverse targets.

[0146] Many of the ligands obtained were similar to those previously reported from a single round of screening also performed on the TPP riboswitch. 15、17Hits in the primary screen appeared to be slightly biased toward higher affinity, such that the majority of ligands detected by SHAPE bound in the 10-300 μM range. The hit detection assay used was likely biased toward detection of the tightest fragment binders, and those that induced the most substantial changes in SHAPE reactivity. Fragments with lower affinities were likely missed. This bias toward tight binding fragments is considered an advantage overall. No fragments were identified that bound to the dengue pseudoknot that reached the affinity and specificity required to meet the screening criteria described above. The dengue pseudoknot RNA is highly structured, and the likelihood that a fragment would disrupt this structure may be low. Another possibility is that this particular pseudoknot structure may not contain a pocket capable of ligand binding.

[0147] The fragment pair discrimination strategy, in which fragment hits from the primary screen were pre-bound to RNA and screened for additional fragment binding partners, specifically exploited the per-nucleotide information obtainable by SHAPE and successfully used this to discover induced compatible fragment pairs (Figure 4). A core tenet of fragment-based ligand development is that cooperativity between two fragments can be achieved by close-proximity binding, and that this additive binding can be exploited by linking the cooperative fragments together using minimally invasive covalent linkers. 20、21、36、37 The development of linked compound 37 from primary and secondary fragment hits indicates that fragment-based ligand discovery can be efficiently applied to RNA targets. There is a weak degree of cooperativity between 2 and 31. Binding by compound 31 was 3-10 times stronger when 2 was pre-bound to RNA. When these two fragments were linked, a weak additivity of their binding energies was observed. 37 had an affinity of 625 nM. No effect beyond additive of linking fragments 2 and 31 was observed, probably because perfect positioning of these fragments was not achieved. 36Small changes in the length or geometry of the linker resulted in large changes in the affinity of the linked ligand (Figure 5), implying that precise positioning of the linker is important to optimally orient the two fragments. The successful development of compound 37 demonstrates that it is not necessary to achieve perfection in either the degree of cooperativity between the fragments or the construction of the covalent linker connecting them to efficiently develop submicromolar ligands.

[0148] There have been numerous efforts designed to exploit interfragment cooperativity to obtain tight-binding ligands targeting proteins, but targeting RNA is in its infancy. Compared to previous (protein-focused) efforts, we examined how well the disclosed SHAPE-based screening strategy combines with fragment ligation. We ranked compounds previously discovered using a fragment-based strategy according to their ligation coefficient (E), which is a measure of how well the whole system works together when ligated. 21、38 (Figure 6, expanded in Table 7). In the absence of positive or negative contributors, the binding energies of the two fragments are exactly additive, the linker is inactive, and E equals 1.0. Cooperative effects or favorable linker interactions lower E, while anticooperative effects or negative linker interactions increase E. Importantly, E values ​​can vary by several orders of magnitude in protein systems. The coupling coefficient of 37 is 2.5, slightly above the average for tethered (protein-targeting) ligands in the academic literature. 37 has a ligand efficiency (LE), calculated as the free energy of binding divided by the number of non-hydrogen atoms, that compares favorably with examples of protein-targeting tethered fragment ligands (Figure 6). By these criteria, 37 performs almost as well as the ligand TPPc, which is closely related to the native TPP riboswitch ligand. 22Thus, fragment-based ligand discovery holds great promise, especially as efficiently implemented by the multiplexed screening that enables SHAPE, allowing the rapid development of unique ligands targeting the vast universe of RNA structures.

[0149] E. Method of Preparation The present disclosure also covers any method for preparing the compounds disclosed herein. Those skilled in the art will recognize that such preparation methods may vary. For example, in some embodiments, the preparation method for the disclosed compounds includes: Fragment of Formula IV [ka] (In the formula, X1, X2, and X3 are independently selected from CHR1, CR1, and heteroatoms N, NH, O, and S, and adjacent X1, X2, and X3 are not simultaneously selected to be O or S; The dashed line represents an optional double bond; Y1, Y2, and Y3 are independently selected from CR2 and N; R1 and R2 are independently selected from -H, -Cl, -Br, -I, -F, -CF3, -OH, -CN, -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -COOH, -COO(C1-C6 alkyl), -CO(C1-C6 alkyl), -O(C1-C6 alkyl), -OCO(C1-C6 alkyl), -NCO(C1-C6 alkyl), -CONHC1-C6(alkyl), and substituted or unsubstituted C1-C6 alkyl; n is selected from the integers 1 and 2, and when n is 1, only one of the dashed lines is a double bond; Fragment of formula V-1 or V-2 [ka] wherein X is a halogen selected from F, Br, Cl, and I; X4, X5, X6, and X7 are independently selected from CR3 and N; R3 is selected from -H, -Cl, -Br, -I, -F, -CF3, -OH, -CN, -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -COOH, -COO(C1-C6 alkyl), -CO(C1-C6 alkyl), -O(C1-C6 alkyl), -OCO(C1-C6 alkyl), -NCO(C1-C6 alkyl), -CONHC1-C6(alkyl), and substituted or unsubstituted C1-C6 alkyl; m is 1 or 2; W is -O or -NR4, R4 is selected from -CO(C1-C6 alkyl), substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, -CO(aryl), -CO(heteroaryl), and -CO(cycloalkyl); contacting in the presence of a Pd catalyst.

[0150] In some embodiments, the Pd catalyst is selected from (DPPF)PdCl2, Pd2(dba)3, PdCl2[P(o-tolyl)3]2, Pd(dba)2, and Pd(OAc)2. In some embodiments, the contacting step further comprises a phosphine ligand. In some embodiments, the phosphine ligand is monodentate. In some embodiments, the phosphine ligand is bidentate. Exemplary phosphine ligands include, but are not limited to, DPPF, BINAP, and rac-BINAP. In some embodiments, the contacting step further comprises a base. In some embodiments, the base is inorganic. In some embodiments, the base is NaOtBu. In some embodiments, the contacting step is performed neat (i.e., without a solvent). In some embodiments, the contacting step is performed in the presence of a solvent. In some embodiments, the solvent is a non-polar solvent. Exemplary solvents include, but are not limited to, toluene, benzene, dioxane, and tetrahydrofuran. In some embodiments, the contacting step is performed at elevated temperatures. In some embodiments, the contacting step is carried out at 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, or 100°C.

[0151] In some embodiments, the method for preparing the disclosed compounds includes: Fragment of Formula IV [ka] with a fragment of formula VI-1 or VI-2 [ka] (wherein X1, X2, X3, X4, X5, X6, X7, Y1, Y2, Y3, n, m, and W are as defined above); and The method includes contacting in the presence of a reducing agent.

[0152] In some embodiments, the reducing agent can be any reducing agent applicable to reductive amination chemistry. Exemplary reducing agents include, but are not limited to, borohydrides and / or aluminum hydrides. In some embodiments, the reducing agent is a borohydride. In some embodiments, the reducing agent is sodium borohydride. In some embodiments, the contacting step is performed without a solvent. In some embodiments, the contacting step is performed in a solvent. Exemplary solvents include, but are not limited to, alcoholic solvents (e.g., methanol, ethanol, isopropanol), chlorinated solvents (e.g., dichloromethane), and / or ethereal solvents (e.g., tetrahydrofuran). In some embodiments, the contacting step is performed below room temperature. In some embodiments, the contacting step is performed at an elevated temperature.

[0153] In some embodiments, the method for preparing the disclosed compounds includes: Fragment of Formula IV [ka] with a fragment of formula VII-1 or VII-2 [ka] (wherein X1, X2, X3, X4, X5, X6, X7, Y1, Y2, Y3, n, m, and W are as defined above; G is -F, -Cl, -Br, -OH, -OCH3, or -OCH2CH3; The contacting step includes contacting in the presence of a base.

[0154] In some embodiments, the base is organic (pyridine and / or trimethylamine). In some embodiments, the base is inorganic (e.g., potassium / sodium carbonate and / or potassium / sodium bicarbonate). In some embodiments, the method further comprises a coupling agent, such as, but not limited to, DCC and / or EDCI. In some embodiments, the contacting step is performed without a solvent. In some embodiments, the contacting step is performed in the presence of a solvent. Exemplary solvents include, but are not limited to, THF, DCM, ACN, and / or DMSO. In some embodiments, the contacting step is performed at room temperature. In some embodiments, the contacting step is performed at an elevated temperature.

[0155] F. Composition The compounds of the present disclosure may be formulated into pharmaceutical compositions together with a pharma- ceutically acceptable carrier.

[0156] The compounds disclosed herein can be formulated according to standard pharmaceutical practice as pharmaceutical compositions. According to this aspect, a pharmaceutical composition is provided that includes a compound disclosed herein in association with a pharma- ceutically acceptable diluent or carrier.

[0157] A typical formulation is prepared by mixing the compound disclosed herein with a carrier, diluent, or excipient. Suitable carriers, diluents, and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water-soluble and / or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc. The particular carrier, diluent, or excipient used depends on the means and purpose for which the compound is applied. Solvents are generally selected based on solvents recognized by those skilled in the art as safe (GRAS) to be administered to mammals. In general, safe solvents are non-toxic aqueous solvents, such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG400, PEG300), etc., and mixtures thereof. The formulation may also include one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifying agents, glidants, processing aids, colorants, sweeteners, fragrances, flavorings, and other known additives to provide an elegant presentation of the drug (i.e., a compound disclosed herein or a pharmaceutical composition thereof) or to aid in the manufacture of a pharmaceutical product (i.e., a medicament).

[0158] The formulation can be prepared using conventional dissolving and mixing procedures. For example, the bulk drug substance (i.e., the compound disclosed herein or a stabilized form of the compound (e.g., a complex with a cyclodextrin derivative or other known complexing agent)) is dissolved in a suitable solvent in the presence of one or more of the above-mentioned excipients. The compound is typically formulated into a pharmaceutical dosage form to provide an easily controllable dosage of the drug and allow patient compliance with the prescribed regimen.

[0159] The pharmaceutical composition (or formulation) for application can be packaged in various ways depending on the method used to administer the drug. Generally, the article for distribution includes a container in which the pharmaceutical formulation is deposited in an appropriate form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, etc. The container may also include a tamper-proof assembly to prevent inadvertent access to the contents of the package. In addition, the container is affixed with a label that describes the contents of the container. The label may also include appropriate warnings.

[0160] Pharmaceutical formulations may be prepared for various routes and types of administration. For example, the compounds disclosed herein having the desired purity may be optionally mixed with a pharma- ceutically acceptable diluent, carrier, excipient, or stabilizer (Remington's Pharmaceutical Sciences (1980) 16th edition, Osol, A. Ed.) in the form of a lyophilized formulation, a milled powder, or an aqueous solution. Formulation may be performed by mixing with a physiologically acceptable carrier (i.e., a carrier that is non-toxic to the recipient at the dosage and concentration used) at an appropriate pH, at the desired purity, and at ambient temperature. The pH of the formulation depends primarily on the particular use and the concentration of the compound, but may range from about 3 to about 8. Formulation in acetate buffer at pH 5 is a preferred embodiment.

[0161] The compounds can be sterile. In particular, formulations to be used for in vivo administration should be sterile. Such sterilization is readily accomplished by filtration through sterile filtration membranes.

[0162] The compounds may typically be stored as solid compositions, lyophilized formulations, or as aqueous solutions.

[0163] Pharmaceutical compositions containing the compounds disclosed herein can be formulated, dosed, and administered in a manner consistent with good medical practice, i.e., amount, concentration, schedule, route, vehicle, and route of administration. Factors to be considered in this context include the particular disorder to be treated, the particular mammal to be treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the administration schedule, and other factors known to physicians. The "therapeutically effective amount" of the compound to be administered is governed by such considerations and is the minimum amount necessary to prevent, ameliorate, or treat a coagulation factor-mediated disorder. Such an amount is preferably below the amount that is toxic to the host or significantly predisposes the host to bleeding.

[0164] Acceptable diluents, carriers, excipients, and stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers including phosphate, citrate, and other organic acids, antioxidants including ascorbic acid and methionine, preservatives (e.g., octadecyldimethylbenzylammonium, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl, or benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol), low molecular weight (less than about 10 residues) polypeptides, serum albumin, gelatin, etc. Examples of suitable surfactants include proteins such as glycines, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine, monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins, chelating agents such as EDTA, sugars such as sucrose, mannitol, trehalose, or sorbitol, salt-forming counterions such as sodium, metal complexes (e.g., Zn-protein complexes), and / or non-ionic surfactants such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG). The active pharmaceutical ingredient may also be encapsulated in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions, e.g., microemulsions prepared by coacervation techniques or by interfacial polymerization, e.g., hydroxymethylcellulose or gelatin-microcapsules and poly(methyl methacrylate) microcapsules, respectively. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0165] Compound sustained release preparations may also be prepared.Suitable examples of sustained release preparations include solid hydrophobic polymer semi-transparent matrix containing the compound disclosed herein, the matrix being in the form of molded article, for example, film, or microcapsule.Examples of sustained release matrix include polyester, hydrogel (for example, poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactide (U.S. Pat. No. 3,773,919), copolymer of L-glutamic acid and gamma-ethyl-L-glutamate, non-degradable vinylene-vinyl acetate, degradable lactic acid-glycolic acid copolymer, for example, LUPRON DEPOT (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.

[0166] The formulations include those suitable for the administration route detailed herein. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the field of pharmacy. Techniques and formulations are generally found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.). Such methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with liquid carriers or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0167] Formulations of the compounds disclosed herein suitable for oral administration can be prepared as discrete units such as pills, capsules, cachets or tablets, each containing a predetermined amount of the compound.

[0168] Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active agent or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets can be optionally coated or scored, and are optionally formulated to provide a slow or controlled release of the active ingredient from the tablet.

[0169] Tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, such as gelatin capsules, syrups, or elixirs can be prepared for oral use. Preparations of the compounds disclosed herein intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents, including sweeteners, flavoring agents, coloring agents, and preservatives, to provide a palatable preparation. Tablets containing the active ingredient in a mixture with non-toxic pharmaceutically acceptable excipients suitable for the manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate, granulating and disintegrating agents, such as corn starch, or alginic acid, binding agents, such as starch, gelatin, or acacia, and lubricants, such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or may be coated by known techniques, including microencapsulation, to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

[0170] For the treatment of the eye or other external tissues, e.g., mouth and skin, the formulations may be applied as a topical ointment or cream containing the active ingredient in an amount of, for example, 0.075 to 20% w / w. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base.

[0171] If desired, the aqueous phase of the cream base may contain polyhydric alcohols, i.e., alcohols having two or more hydroxyl groups, such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol, and polyethylene glycol (including PEG 400), and mixtures thereof. It may be desirable for topical formulations to include compounds that enhance absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such skin penetration enhancers include dimethyl sulfoxide and related analogues.

[0172] The oily phase of the emulsion may be composed of known ingredients in a known manner. The phase may contain only emulsifiers, but may also contain at least one emulsifier and a fat or oil, or a mixture of both fats and oils. The hydrophilic emulsifiers included with the lipophilic emulsifiers may function as stabilizers. Together, the emulsifiers, with or without stabilizers, constitute the so-called emulsifying waxes, which, together with the oils and fats, constitute the so-called emulsifying ointment bases that form the oily dispersed phase of the cream formulation. Emulsifiers and emulsion stabilizers suitable for use in the formulation include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate.

[0173] Aqueous suspension of compound contains active material in mixture with excipient suitable for making aqueous suspension. Such excipients include suspending agents such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as naturally occurring phosphatides (e.g., lecithin), condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearates), condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., heptadecaethyleneoxycetanol), condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyoxyethylene sorbitan monooleate). Aqueous suspension may also contain one or more preservatives, such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0174] The pharmaceutical composition of the compound may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. The suspension may be formulated according to known techniques using those suitable dispersing or wetting agents and suspending agents mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as 1,3-butanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils may be conventionally used as a solvent or suspending medium. For this purpose, any brand of fixed oil may be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may also be used in the preparation of injectables.

[0175] The amount of active ingredient that may be combined with carrier materials to produce a single dosage form will vary depending on the host treated and the particular mode of administration. For example, a time-release formulation intended for oral administration to humans may contain about 1-1000 mg of active ingredient mixed with an appropriate and convenient amount of carrier material, which may vary from about 5 to about 95% (weight:weight) of the total composition. Pharmaceutical compositions may be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain about 1-500 μg of active ingredient per milliliter of solution, such that infusion of a suitable volume at a rate of about 10 mL / hour to about 50 mL / hour may occur.

[0176] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

[0177] Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of about 0.5-20% w / w, for example about 0.5-10% w / w, for example about 1.5% w / w.

[0178] Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth, pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0179] Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

[0180] Formulations suitable for pulmonary or nasal administration have, for example, a particle size in the range of 0.1 to 500 microns (including particle sizes in the range of 0.1 to 500 microns in micron increments such as 0.5, 1, 30 microns, 35 microns, etc.) and are administered by rapid inhalation through the nasal passage or by inhalation through the oral cavity to reach the alveolar sacs. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents, such as compounds previously used in the treatment or prevention of disorders described below.

[0181] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0182] The formulations may be packaged in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a frozen and dried (lyophilized) state, requiring only the addition of a sterile liquid carrier, for example water, for injection immediately prior to use.Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the type previously described.Preferred unit dosage formulations are those that contain a daily dose or daily sub-dose (as listed hereinabove) of active ingredient, or an appropriate fraction thereof.

[0183] The present subject matter further provides veterinary compositions comprising at least one active ingredient as defined above together with a veterinary carrier. The veterinary carrier is a material useful for the purpose of administering the composition and may be a solid, liquid, or gaseous material that is otherwise inert or acceptable in the veterinary art and compatible with the active ingredient. These veterinary compositions may be administered parenterally, orally, or by any other desired route.

[0184] In certain embodiments, a pharmaceutical composition comprising a compound of the present disclosure further comprises a chemotherapeutic agent. In some of these embodiments, the chemotherapeutic agent is an immunotherapeutic agent.

[0185] G. Treatment Methods The compounds and compositions disclosed herein can also be used in methods for treating various diseases and / or disorders identified as associated with dysfunction of RNA expression and / or function, or expression and / or function of proteins produced from mRNA, or the useful role of switching RNA conformation using small molecules, or altering the natural function of riboswitches as a method to inhibit growth of infectious organisms. Thus, the methods of the present disclosure are directed to treating diseases or disorders associated with dysfunction of RNA expression and / or function, or to creating new switchable therapeutics. See, for example, U.S. Patent Application Publication No. 2018 / 010146, which is incorporated herein by reference in its entirety. Thus, in some embodiments, a method for treating a disease or disorder disclosed herein (e.g., associated with dysfunction of RNA expression and / or function) comprises administering to a subject in need thereof a dose of a therapeutically effective amount of a compound and / or composition disclosed herein.

[0186] The dysfunction of RNA expression is characterized by over- or under-expression of one or more RNA molecules. In some embodiments, the one or more RNA molecules are associated with promoting the disease and / or disorder being treated. In some embodiments, the RNA molecules are characterized as being part of the machinery of a healthy cell, thus preventing and / or ameliorating the disease and / or disorder being treated. In some embodiments, the disease or disorder being treated is associated with dysfunction of RNA function associated with transcription, processing, and / or translation. In some embodiments, the disease or disorder being treated is associated with incorrect expression of a protein as a result of dysfunctional RNA molecule function. In some embodiments, the disease or disorder being treated is associated with dysfunction of RNA function associated with gene expression. In some embodiments, the disease or disorder is a disease or disorder in which it is desired to reduce protein expression by binding a molecule to the mRNA. In some embodiments, the disease is advantageously treated by a therapy that can be switched on or off using a small molecule. For example, in some embodiments, the disease or disorder is a genetic disease in which it is desired to have the ability to switch on or off the expression of a therapeutic gene.

[0187] The diseases or disorders to be treated include, but are not limited to, degenerative disorders, cancer, diabetes, autoimmune disorders, cardiovascular disorders, coagulation disorders, eye diseases, infectious diseases, and diseases caused by mutations in one or more genes.

[0188] Exemplary degenerative diseases include, but are not limited to, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), cancer, Charcot-Marie-Tooth disease (CMT), chronic traumatic encephalopathy, cystic fibrosis, some cytochrome c oxidase deficiencies (often the cause of degenerative Leigh syndrome), Ehlers-Danlos syndrome, fibrodysplasia ossificans progressiva, Friedreich's ataxia, frontotemporal dementia (FTD), some cardiovascular diseases (e.g., coronary artery disease, atherosclerosis such as aortic stenosis), Huntington's disease, infantile neuroaxonal dystrophy, keratoconus (KC), keratoglobulosa, leukodystrophies, macular degeneration (AMD), Marfan's disease, and the like. These diseases include myelopathy, myelopathy, myelopathy with mitochondrial DNA depletion syndrome ...

[0189] Exemplary cancers include, but are not limited to, all forms of carcinoma, melanoma, blastoma, sarcoma, lymphoma and leukemia, including, but not limited to, bladder cancer, bladder carcinoma, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, endometrial cancer, hepatocellular carcinoma, laryngeal cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney and thyroid cancer, acute lymphocytic leukemia, acute myeloid leukemia, ependymoma, Ewing's sarcoma, glioblastoma, medulloblastoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, rhabdoid carcinoma, and nephroblastoma (Wilm's tumor).

[0190] Exemplary autoimmune disorders include, but are not limited to, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune autonomic dysfunction, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal neuropathy (AMAN), Baro's disease, Behcet's disease, benign mucous membrane pemphigoid, bullous pemphigoid, Cass' disease, and the like. Celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic relapsing multifocal osteomyelitis (CRMO), Churg-Strauss syndrome (CSS) or eosinophilic granulomatosis (EGPA), cicatricial pemphigoid, Cogan syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schönlein purpura (HSP), herpes gestationis or pemphigoid of gestationis (PG), hidradenitis suppurativa (HS) (acne inversa), hypogammaglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura (ITP), inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes mellitus ( Type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, lignified conjunctivitis, linear immunoglobulin A disease (LAD), lupus, chronic Lyme disease, Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren's ulcer, Mucca-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, relapsing rheumatoid arthritis (PR), PANDAS,Paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry-Romberg syndrome, pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndrome types I, II, and III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, post-pericardiotomy syndrome, primary biliary cholangitis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, recurrent inflammatory bowel disease, These include: progressive polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleroderma, Sjögren's syndrome, autoimmune spermatozoonotic dysgenesis, stiff-person syndrome (SPS), subacute bacterial endocarditis (SBE), Sazac syndrome, sympathetic ophthalmia (SO), Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), transverse myelitis, type 1 diabetes mellitus, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, and Vogt-Koyanagi-Harada disease.

[0191] Exemplary cardiovascular disorders include, but are not limited to, coronary artery disease (CAD), angina, myocardial infarction, stroke, heart attack, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathies, abnormal heart rhythms, congenital heart disease, valvular heart disease, carditis, aortic aneurysm, peripheral arterial disease, thromboembolic disease, and venous thromboembolism.

[0192] Exemplary coagulation disorders include, but are not limited to, hemophilia, von Willebrand's disease, disseminated intravascular coagulation, liver disease, excesses of circulating anticoagulants, vitamin K deficiency, platelet dysfunction, and other coagulation defects.

[0193] Exemplary eye diseases include, but are not limited to, macular degeneration, exophthalmos, cataracts, CMV retinitis, diabetic macular edema, glaucoma, keratoconus, ocular hypertension, ocular migraine, retinoblastoma, subconjunctival hemorrhage, pterygium, keratitis, dry eye, and corneal abrasion.

[0194] Exemplary infectious diseases include, but are not limited to, acute flaccid myelitis (AFM), anaplasmosis, anthrax, babesiosis, botulism, brucellosis, campylobacteriosis, carbapenem-resistant infections (CRE / CRPA), chancroid, chikungunya virus infection (chikungunya), chlamydia, ciguatera (toxic algal bloom (HAB)), Clostridium Difficile infection, Clostridium Perfringens (epsilon toxin), Coccidioides fungal infection (Valley fever), COVID-19 (Coronavirus Disease 2019), Creutzfeldt-Jakob disease, Transmissible spongiform encephalopathy (CJD), Cryptosporidiosis (Crypto), Cyclosporosis, Dengue 1,2,3,4 (Dengue fever), Diphtheria, E. coli infection, Shiga toxin producing (STEC), Eastern equine encephalitis (EEE), Ebola hemorrhagic fever (Ebola ), ehrlichiosis, encephalitis, arbovirus or parainfectious, enterovirus infection, nonpolio (nonpolioenterovirus), enterovirus infection, D68 (EV-D68), giardiasis (giardia), glanders, gonorrhea (gonorrhea), granuloma inguinale, Haemophilus influenzae infection, type B (Hib or H-flu), Hantavirus pulmonary syndrome (HPS), hemolytic uremic syndrome (HUS), hepatitis A (Hep A), Hepatitis B (Hep B), Hepatitis C (Hep C), Hepatitis D (Hep D), Hepatitis E (Hep E), Herpes, Shingles, Chickenpox VZV (Shigelle), Histoplasmosis (Histoplasmosis), Human Immunodeficiency Virus / AIDS (HIV / AIDS), Human Papilloma Virus (HPV), Influenza (Flu), Lead Poisoning, Legionnaires' Disease (Legionnaires' Disease), Leprosy (Hansen's Disease), Leptospirosis, Listeriosis (Listeria), Lyme Disease, Lymphogranuloma venereum infection (LGV), malaria, measles, melioidosis, meningitis, viral (meningitis, viral), meningococcal infection, bacterial (meningitis, bacterial), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), mumps, norovirus, paralytic shellfish poisoning (paralytic shellfish poisoning, ciguatera), pediculosis (head and body lice), pelvic inflammatory disease (PID), whooping cough (Pertussis (Whooping Cough)Cough) plague, bubonic, septicemic, pulmonary (plague), pneumococcal infection (pneumonia), poliomyelitis (polio), Powassan, psittacosis (parrot fever), psoriasis (hair lice, pubic lice infection), pustular psoriasis (smallpox, monkeypox, cowpox), Q fever, rabies, ricin poisoning, rickettsiosis (Rocky Mountain spotted fever), rubella, congenital (three-day measles), Salmonella gastroenteritis (Salmonella), scabies infection (scabies), scombroid, septicemic Shock (Sepsis), Severe Acute Respiratory Syndrome (SARS), Shigella gastroenteritis (Shigella), Smallpox, Staphylococcus aureus infection, Methicillin-resistant (MRSA), Staphylococcus aureus food poisoning, Enterotoxin-B poisoning (Staphylococcus aureus food poisoning), Staphylococcus aureus infection, Vancomycin-intermediate resistance (VISA), Staphylococcus aureus infection, Vancomycin-resistant (VRSA), Streptococcus infection, Group A (invasive) (Strep A (invasive), Streptococcal infection, Group B (Strep-B), Streptococcal toxic shock syndrome, STSS, toxic shock (STSS, TSS), Syphilis (primary, secondary, early latent, latent, congenital), Tetanus infection, Tetanus (opening), Trichomoniasis (Trichonosis), Trichomonas infection, Tuberculosis (TB), Tuberculosis (latent) (LTBI), Tularemia (Rabbit fever), Typhoid fever (Group D), Typhoid, Vaginitis, Bacterial (yeast infection), Vaping-associated lung injury, Chickenpox infection, Vibrio cholerae, Vibrio infections (Vibrio), viral hemorrhagic fevers (Ebola, Lassa, Marburg), West Nile virus, yellow fever, Yersinia infections (Yersinia), and Zika virus infection (Zika). EXAMPLES

[0195] Example 1: RNA construct design and preparation The screening constructs were designed to allow for the incorporation of a wide variety of one or more internal target RNA motifs. The following two motifs were present in the constructs: TPP riboswitch domain 27 , and a pseudoknot from the 5'-UTR of dengue virus 26The design for the complete construct sequence, including the structural cassette, the RNA barcode helix, and the two test RNA structures (separated by a 6-nucleotide linker), was evaluated using the RNA structures. 39 To reduce the possibility that the two test structures would interact, a small number of sequence changes were made to prevent misfolding predicted by the RNA structure while retaining the native fold (Figure 7). The structure of the final construct was confirmed by SHAPE-MaP.

[0196] RNA barcodes were designed to fold into self-containing hairpins (Figure 7). All possible permutations of the RNA barcodes were calculated and folded in the context of the entire construct sequence, and any barcodes that had the potential to interact with another part of the RNA construct were removed from this set. The barcoded constructs were probed with SHAPE-MaP using a "ligand-free" protocol and folded using an RNA structure with SHAPE-responsive constraints to confirm that the barcode helix folded into the desired self-containing hairpin.

[0197] Preparation of RNA The DNA template for in vitro transcription (Integrated DNA Technologies) consisted of the target construct sequence (containing a dengue pseudoknot sequence, a single-stranded linker, and a TPP riboswitch sequence) and an adjacent structural cassette. 25 was coded.

number

number

[0198] DNA was amplified by PCR to generate templates for in vitro transcription using 200 μM dNTP mix (New England Biolabs), 500 nM forward primer, 500 nM reverse primer, 1 ng DNA template, 20% (v / v) Q5 reaction buffer, and 0.02 U / μL Q5 Hot Start High Fidelity Polymerase (New England Biolabs). DNA was purified (PureLink Pro 96 PCR Purification Kit, Invitrogen) and quantified (Quant-iT dsDNA High Sensitivity Assay Kit, Invitrogen) on a Tecan Infinite M1000 Pro microplate reader.

[0199] In vitro transcription was performed in a 96-well plate format with each well containing 100 μL total reaction volume in 25 mM MgCl2, 40 mM Tris (pH 8.0), 2.5 mM spermidine, 0.01% Triton, 10 mM DTT, and 200-800 nM of uniquely barcoded DNA template (generated by PCR), 5 mM NTPs (New England Biolabs), 0.02 U / μL inorganic pyrophosphatase (yeast, New England Biolabs), and 0.05 mg / mL T7 polymerase. The reactions were incubated at 37°C for 4 hours, then treated with TurboDNase (RNase-free, Invitrogen) at a final concentration of 0.04U / μL and incubated at 37°C for 30 minutes, after which a second DNase was added to a total final concentration of 0.08U / μL and incubated at 37°C for an additional 30 minutes. The enzymatic reaction was stopped by adding EDTA to a final concentration of 50 mM and placed on ice. RNA was purified in a 96-well format (Agencourt RNAclean XP magnetic beads, Beckman Coulter) and resuspended in 10 mM Tris (pH 8.0), 1 mM EDTA. RNA concentrations were quantified (Quant-iT RNA broad range assay kit, Invitrogen) with a Tecan Infinite M1000 Pro microplate reader, and the RNA in each well was individually diluted to 1 pmol / μL. RNA was stored at -80°C.

[0200] Example 2: Chemical modification and screening of small molecule fragments The fragments were obtained as a fragment screening library from Maybridge, a subset of their Ro3 diversity fragment library, containing 1500 compounds dissolved in DMSO at 50 mM. The majority of these compounds adhered to the "rule of three" for fragment compounds: having a molecular mass less than 300 Da, containing no more than three hydrogen bond donors and no more than three hydrogen bond acceptors, and ClogP ≦ 3.0. All compounds used for ITC, except for those listed in Example 5, were purchased from Millipore-Sigma and used without further purification. Screening experiments were performed in 25 μL in 96-well plate format on a Tecan Freedom Evo-150 liquid handler fitted with an 8-channel air-changing pipetting arm, disposable filter tips, a robotic manipulator arm, and an EchoTherm RIC20 remote-controlled heating / cooling dry bath (Torrey Pines Scientific). The program for the liquid handler used for screening is available upon request.

[0201] For the first fragment-ligand screen, 5 pmol of RNA per well was diluted to 19.6 μL in RNase-free water on a 4° C. cooling block. The plate was heated to 95° C. for 2 minutes and immediately quick-chilled at 4° C. for 5 minutes. To each well, 19.6 μL of 2x folding buffer (final concentrations of 50 mM HEPES pH 8.0, 200 mM potassium acetate, and 10 mM MgCl2) was added and the plate was incubated at 37° C. for 30 minutes. For the second fragment-ligand screen, 24.3 μL of folded RNA per well was diluted to 2.7 μL of primary binding fragment in DMSO for a final concentration of K of the fragment. d10x SHAPE reagent in DMSO was added to the wells and the samples were incubated at 37°C for 10 min. To combine the target RNA with the fragments, 24.3 μL of RNA solution or RNA and primary binding fragments were added to wells containing 2.7 μL of 10x screening fragments (in DMSO, resulting in a final fragment concentration of 1 mM). The solutions were mixed thoroughly by pipetting and incubated at 37°C for 10 min. For SHAPE probing, 22.5 μL of RNA fragment solution from each well of the screening plate was added to 2.5 μL of 10x SHAPE reagent in DMSO on a 37°C heating block and mixed quickly by pipetting to achieve uniform distribution of SHAPE reagent and RNA. After the appropriate reaction time, the samples were placed on ice. For the first fragment screening, 1-methyl-7-nitroisatoic anhydride (1M7) was used as the SHAPE reagent at a final concentration of 10 mM and reacted for 5 min. For the second fragment screening, 5-nitroisatoic anhydride (5NIA) ​​was used as the SHAPE reagent at a final concentration of 10 mM. 40 was used as the SHAPE reagent at a final concentration of 25 mM and reacted for 15 min. Excess fragments, solvent, and hydrolyzed SHAPE reagent were removed using AutoScreen-A 96-Well Plates (GE Healthcare Life Sciences), and 5 μL of modified RNA from each well of the 96-well plate was pooled into a single sample per plate for sequencing library preparation.

[0202] Each screen consisted of 19 fragment test plates, two plates containing a distribution of positive (fragment 2, 1 mM final concentration) and negative (solvent, DMSO) controls, and one negative SHAPE control plate treated with solvent (DMSO) instead of SHAPE reagent. For hit validation experiments, the well location of each hit fragment was varied to control for well location and RNA barcode effects. Plate maps for both the primary and secondary screens were available as well.

[0203] Once screening of the test fragments is complete, a statistical test is performed to identify differences in the modification rate of a given nucleotide. Specifically, the screening analysis requires a statistical comparison of the modification rate of a given nucleotide in the presence of a fragment compared to the absence of the fragment. For each nucleotide, the number of modifications in a given reaction is a Poisson process with known variance, and therefore the statistical significance of the observed difference in modification rate between two samples is determined using a Comparison of Two Poisson Counts test. 31 That is, if m1 modifications of the tested nucleotide are counted in n1 reads of sample 1 and m2 modifications are counted in n2 reads of sample 2, then the null hypothesis being tested predicts that the proportion of modifications in sample 1 among all counted modifications (m1+m2) is p1=n1 / (n1+n2). A Z-test of this hypothesis is

number

number

[0204] If the Z-score exceeds a specified significance threshold, the tested nucleotide is interpreted as being statistically significantly affected by the presence of the test fragment.

[0205] Next, for each fragment, Z-tests need to be performed on a large number of nucleotides that comprise the RNA sequence, increasing the probability of a false positive. The number of false positive assignments of SHAPE reactivity per nucleotide can be minimized by raising the Z-significance threshold, but this approach reduces the sensitivity of the screen (meaning it reduces the ability to detect weaker binding ligands). To reduce the number of Z-tests performed, such tests were applied only to nucleotides in the region of interest rather than to all nucleotides in the RNA screening construct. For the dengue motif in the RNA, the region of interest was positions 59-110. For the TPP motif, the region of interest was positions 100-199. The number of Z-tests was further reduced by omitting nucleotides that had low modification rates in both samples. The threshold for considering a nucleotide as having a low modification rate was set to 25% of the plate-average modification rate calculated across all nucleotides in all 96 wells of a given plate. Z-tests were performed only on nucleotides that had a modification rate above this 25% threshold in at least one of the two compared samples.

[0206] Ideally, the only difference between conditions in the two compared samples would be the presence of the fragment in one sample but not the other. Testing negative control samples against each other can be used to determine the incidence of uncontrollable factors that may introduce inter-sample variation in nucleotide modification rates. For example, if the Z significance threshold is set at 2.7, in the absence of any such factors, a Z test applied to pairs of negative control (no fragment) samples should theoretically identify differently reactive nucleotides with a probability of P=0.0035. However, when the Z test is applied to pairs of negative control samples randomly selected from the 587 negative control samples tested in the primary screen, the actual probability was P=0.32, 90 times higher. Thus, at individual nucleotides, there was statistically significant variation in SHAPE reactivity in the absence of the fragment.

[0207] Although the majority of replicates shared essentially the same profile, there were a significant number of replicates with different profiles. Some coefficients of determination were as low as 0.85. Application of the Z-test to different negative control samples produced numerous cases in which nucleotides were erroneously classified as differentially reactive. To avoid this outcome, each sample was compared to the five most highly correlated negative control samples. A Z-test applied to such selective pairs of negative controls with a Z-significance threshold of 2.7 identified differentially reactive nucleotides with probability P=0.067.

[0208] This probability is about 20-fold higher than the theoretical P=0.0035, indicating that there is variation in sample processing. Some of this variation is present on an equal scale across the reactivity of all nucleotides of all RNAs in the sample. This variation can be removed by scaling down the overall reactivity in the more reactive samples to match the overall reactivity in the less reactive samples. Such scaling was performed by (i) calculating for each nucleotide in the RNA sequence the ratio of the modification rate in the more reactive samples to the modification rate in the less reactive samples, and (ii) dividing the modification rate of all nucleotides in the more reactive samples by the median of the ratios obtained in step (i). Such scaling of the pairs that maximized the correlation of the negative control wells reduced the probability of finding a nucleotide hit to P=0.030, which was 9-fold higher than the theoretical probability. Thus, false positive identification of fragments occurs as it does in practically all high-throughput screening assays, and real fragment hits from non-ligand variation were distinguished by replicate SHAPE validation and direct ligand binding measurements using ITC.

[0209] Since an effective ligand is expected to affect the modification rate of multiple nucleotides in the target RNA, a fragment was recognized as a hit only if the number of nucleotides with different reactivity from the negative control exceeded a predefined threshold, which was set at 2. Second, when exploring a relatively stable effect of a fragment on RNA, small relative differences in the reactivity of nucleotides were excluded from the total number of differently reactive nucleotides, even if they were statistically significant. In practice, the minimum acceptable difference was set at 20% of the mean, |r1-r2| / (r1+r2) / 2=0.2, Wherein r1 and r2 are the nucleotide modification rates in two samples.Thirdly, a given sample was tested against the five most highly correlated negative control samples.All five tests were required to find the test sample that changed against the negative control sample.

[0210] Finally, the sensitivity and specificity of the screen were controlled by the choice of Z-significance threshold. The fragment-containing samples and all negative control samples were evaluated at multiple Z-significance threshold settings. For each such setting, the false positive fragment (FPF) was calculated as the fraction of negative control samples found to be altered, and the ligand fraction (LF) was estimated by subtracting the FPF from the fraction of altered samples containing the fragment. The balance between LF and FPF was quantified by their ratio, LF / FPF. The best balance of TPP riboswitch RNA

number

number

[0211] Example 3: Library preparation and sequencing Reverse transcription was performed on pooled modified RNA in a volume of 100 μL. To 71 μL of pooled RNA, 6 μL of reverse transcription primer was added to achieve a final primer concentration of 150 nM, and the sample was incubated at 65° C. for 5 minutes and then placed on ice. To this solution, 6 μL of 10x first strand buffer (500 mM Tris pH 8.0, 750 mM KCl), 4 μL of 0.4 M DTT, 8 μL of dNTP mix (10 mM each), and 15 μL of 500 mM MnCl2 were added, and the solution was incubated at 42° C. for 2 minutes before adding 8 μL of SuperScript II Reverse Transcriptase (Invitrogen). The reaction was incubated at 42° C. for 3 hours, followed by heat inactivation at 70° C. for 10 minutes and then placed on ice. The resulting cDNA product was purified (Agencourt RNAClean magnetic beads, Beckman Coulter), eluted in RNase-free water, and stored at −20° C. The sequence of the reverse transcription primer was 5′-CGGGC TTCGG TCCGG TTC-3′ (SEQ ID NO: 3).

[0212] Amplify DNA and add required TruSeq adapters 24DNA libraries were prepared for sequencing using a two-step PCR reaction to add 200 μM dNTP mix (New England Biolabs), 500 nM forward primer, 500 nM reverse primer, 1 ng cDNA or double-stranded DNA template, 20% (v / v) Q5 reaction buffer (New England Biolabs), and 0.02 U / μL Q5 Hot Start High Fidelity Polymerase (New England Biolabs). Excess unincorporated dNTPs and primers were removed by affinity purification (Agencourt AmpureXP magnetic beads, Beckman Coulter, with a sample to bead ratio of 0.7:1). DNA libraries were quantified (Qubit dsDNA High Sensitivity Assay Kit, Invitrogen) with a Qubit fluorometer (Invitrogen), quality checked (Bioanalyzer 2100 on-chip electrophoresis instrument, Agilent), and sequenced on an Illumina NextSeq 550 high-throughput sequencer.

[0213] SHAPE-MaP library preparation amplicon-specific forward primers were

number

number

[0214] Example 4: Isothermal Titration Calorimetry ITC experiments were performed under RNase-free conditions using a Microcal PEAQ-ITC automated instrument (Malvern Analytical).41 In vitro transcribed RNA was exchanged into folding buffer containing 100 mM CHES (pH 8.0), 200 mM potassium acetate, and 3 mM MgCl2 using a centrifugation filter (Amicon Ultra centrifugal filter, 10K MWCO, Millipore-Sigma). Ligand was dissolved in the same buffer at a concentration 10-20x the desired experimental concentration of RNA (to minimize heat of mixing when ligand was added to RNA). RNA concentration was quantified (Nanodrop UV-VIS spectrometer, ThermoFisher Scientific) and the expected K in the buffer was calculated. d The RNA was diluted from 1 to 10 times the concentration and the diluted RNA was re-quantified to confirm the final experimental RNA concentration. The RNA diluted in folding buffer was heated at 65 °C for 5 min, placed on ice for 5 min, and folded at 37 °C for 15 min. If necessary, the primary binding ligand (e.g., 2) was pre-bound to the RNA by adding 0.1 volumes at 10x the desired final concentration of bound ligand, followed by incubation at room temperature for 10 min.

[0215] Each ITC experiment involved two trials, one in which the ligand was titrated into RNA (experimental trace) and one in which the same ligand was titrated into buffer (control trace). ITC experiments were performed using the following parameters: cell temperature of 25°C, reference power of 8 μCal / sec, stirring speed of 750 RPM, high feedback mode, initial injection of 0.2 μL followed by 19 injections of 2 μL. Each injection required 4 seconds to complete, with a 180 second interval between injections.

[0216] ITC data were analyzed using MicroCal PEAQ-ITC Analysis Software (Malvern Analytical). First, the baseline for each injection peak was manually adjusted to eliminate erroneously selected injection end points. Second, the control trace was subtracted from the experimental trace by point-to-point subtraction. Third, a least-squares regression line was fitted to the data using the Levenberg-Marquardt algorithm. For weakly binding ligands (>500 μM), N was manually set to 1.0 to allow for fitting of low c-value curves.

[0217] Example 5: Chemical synthesis of test compounds 35, 36, 37, 38, 39, and 40 [ka] Compound 35: The 3-C linked hydroxamic acid 35 was prepared from carboxylic acid S19 via a mixed anhydride intermediate by reaction with aqueous hydroxylamine. Acid S19 was obtained by treatment of quinoxalin-6-amine with cyclized dihydrofuran-2,5-dione anhydride.

[0218] [ka] Compound 36: The 2-C linked analog 36 was obtained from the corresponding ester S20 by reaction with hydroxylamine formed in situ. Ester S20 was made by Michael addition of quinoxalin-6-amine with ethyl acrylate.

[0219] [ka] Compound 37: For the synthesis of intermediates S21 and S22, the Buchwald-Hartwig reaction was used. Removal of the protecting group (Boc) was achieved using HCl in ether, followed by further treatment with Na2CO3 to give 37.

[0220] [ka] Compound 38: Imine formation followed by sodium borohydride reduction of quinoxaline-6-carbaldehyde and the diamine gave 38.

[0221] [ka] Compound 39: Imine formation and subsequent sodium borohydride reduction of quinoxalin-6-ylmethanamine hydrochloride and aldehyde S23, S N Ar reaction gave intermediate S24, which after (Boc) deprotection with HCl gave 39.

[0222] [ka] Compound 40: The less constrained analog 40 was generated by two Buchwald-Hartwig reactions with 3,5-dibromopyridine followed by (Boc) deprotection with HCl.

[0223] Example 6: X-ray crystallography To assess whether the structural variants of 2 are good binding candidates for the TPP riboswitch, compound 17 was examined in X-ray crystallographic studies. TPP riboswitch RNA was prepared by in vitro transcription as described. 27TPP riboswitch RNA (0.2 mM) and 17 (2 mM) were crystallized in a buffer containing 50 mM potassium acetate (pH 6.8) and 5 mM MgCl2 after heating at 60 °C for 3 min, rapid cooling on crushed ice, and incubation at 4 °C for 30 min. For crystallization, 1.0 μL of the RNA-17 complex was mixed with 1.0 μL of a stock solution containing 0.1 M sodium acetate (pH 4.8), 0.35 M ammonium acetate, and 28% (v / v) PEG4000. Crystallization was performed at 291 K by hanging drop vapor diffusion over a 2-week period. Crystals were cryoprotected in mother liquor supplemented with 15% glycerol and then rapid frozen in liquid nitrogen. Data were collected at NSLS-II (Brookhaven National Laboratory), 17-ID-2 (FMX) beamline, wavelength 0.9202 Å. Data were processed with HKL200043. The structure was solved by molecular replacement using Phenix44 and the 2GDI riboswitch RNA structure. 27 The structure was refined in Phenix. Organic ligands, water molecules and ions were added at a later stage of refinement based on the Fo-Fc and 2Fo-Fc electron density maps.

[0224] The results showed that compound 17 stacks between G42 and A43 in the J3 / 2 junction and binds to the TPP riboswitch in a manner similar to the thiamine moiety of the TPP ligand (Figure 3). 27、28 17 forms three hydrogen bonds with the RNA, one each to the ribose and Watson-Crick face of G40 and one to the ribose of G19. There is a significant change in the local RNA structure compared to the RNA in complex with the native TPP ligand. In the 17-bound structure, G72 is flipped within the binding site where the pyrophosphate moiety of the TPP ligand resides. This binding mode is consistent with previous studies that visualized a flipped G72 orientation for fragments bound to the thiamine subsite of the riboswitch binding pocket. 17、34Consistent with the SAR analysis, the orientation of the C-6 substituent appears to be relatively unhindered by interactions with RNA, implying that this vector would be a good candidate for fragment purification.

[0225] References 1. Hajduk, PJ, Huth, JR & Tse, C. Predicting protein druggability. Drug Discov. Today 10, 1675-1682 (2005). 2.Vukovic, S. & Huggins, DJQuantitative metrics for drug-target ligandability.Drug Discov.Today 23, 1258-1266(2018). 3. Batey, RT, Rambo, RP & Doudna, JATertiary Motifs in RNA Structure and Folding. Angew. Chem. Int. Ed. 38, 2326-2343 (1999). 4.Warner,KD,Hajdin,CE& Weeks,KMPrinciples for targeting RNA with drug-like small molecules.Nat.Rev.Drug Discov.17,547-558(2018). 5. Sharp, PA The Centrality of RNA. Cell 136, 577-580 (2009). 6. Kozak, M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 361, 13-37 (2005). 7.Corbino,KA,Sherlock,ME,McCown,PJ,Breaker,RR& Stav,S.Riboswitch diversity and distribution.RNA 23,995-1011(2017). 8.Cech,T.R.& Steitz,J.A.The noncoding RNA revolution-Trashing old rules to forge new ones.Cell 157,77-94(2014). 9.Parsons,C.,Slack,F.J.,Zhang,W.C.,Adams,B.D.& Walker,L.Targeting noncoding RNAs in disease.J.Clin.Invest.127,761-771(2017). 10.Matsui,M.& Corey,D.R.Non-coding RNAs as drug targets.Nat.Rev.Drug Discov.16,167-179(2017). 11.Guan,L.& Disney,M.D.Recent advances in developing small molecules targeting RNA.ACS Chem.Biol.7,73-86(2012). 12.Connelly,C.M.,Moon,M.H.& Schneekloth,J.S.The Emerging Role of RNA as a Therapeutic Target for Small Molecules.Cell Chem.Biol.23,1077-1090(2016). 13.Murray,C.W.& Rees,D.C.The rise of fragment-based drug discovery.Nat.Chem.1,187-92(2009). 14.Doak,B.C.,Norton,R.S.& Scanlon,M.J.The ways and means of fragment-based drug design.Pharmacol.Ther.167,28-37(2016). 15.Cressina,E.,Chen,L.,Abell,C.,Leeper,F.J.& Smith,A.G.Fragment screening against the thiamine pyrophosphate riboswitch thiM.Chem.Sci.2,157-165(2011). 16.Moumne,R.,Catala,M.,Larue,V.,Micouin,L.& Tisne,C.Fragment-based design of small RNA binders:Promising developments and contribution of NMR.Biochimie 94,1607-1619(2012). 17.Warner,K.D.et al.Validating fragment-based drug discovery for biological RNAs:Lead fragments bind and remodel the TPP riboswitch specifically.Chem.Biol.21,591-595(2014). 18.Zeiger,M.et al.Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR.Bioorganic Med.Chem.Lett.24,5576-5580(2014). 19.Bottini,A.et al.Targeting Influenza A Virus RNA Promoter.Chem.Biol.Drug Des.86,663-673(2015). 20.Hunter,C.A.& Anderson,H.L.What is cooperativity? Angew.Chemie-Int.Ed.48,7488-7499(2009). 21.Ichihara,O.,Barker,J.,Law,R.J.& Whittaker,M.Compound design by fragment-linking.Mol.Inform.30,298-306(2011). 22.Zeller,M.J.,Li,K.,Aube,J.& Weeks,K.M.Multisite ligand recognition and cooperativity in the TPP riboswitch RNA.Prep.(2019). 23.Siegfried,N.A.,Busan,S.,Rice,G.M.,Nelson,J.A.E.& Weeks,K.M.RNA motif discovery by SHAPE and mutational profiling(SHAPE-MaP).Nat.Methods 11,959-65(2014). 24.Smola,M.J.,Rice,G.M.,Busan,S.,Siegfried,N.A.& Weeks,K.M.Selective 2’-hydroxyl acylation analyzed by primer extension and mutational profiling(SHAPE-MaP) for direct,versatile and accurate RNA structure analysis.Nat.Protoc.10,1643-1669(2015). 25.Merino,E.J.,Wilkinson,K.A.,Coughlan,J.L.& Weeks,K.M.RNA structure analysis at single nucleotide resolution by selective 2’-hydroxyl acylation and primer extension(SHAPE).J.Am.Chem.Soc.127,4223-4231(2005). 26.Liu,Z.-Y.et al.Novel cis-acting element within the capsid-coding region enhances flavivirus viral-RNA replication by regulating genome cyclization.J.Virol.87,6804-18(2013). 27.Serganov,A.,Polonskaia,A.,Phan,A.T.,Breaker,R.R.& Patel,D.J.Structural basis for gene regulation by a thiamine pyrophosphate-sensing riboswitch.Nature 441,1167-1171(2006). 28.Edwards,T.E.& Ferre-D’Amare,A.R.Crystal structures of the thi-box riboswitch bound to thiamine pyrophosphate analogs reveal adaptive RNA-small molecule recognition.Structure 14,1459-68(2006). 29.Thore,S.,Frick,C.& Ban,N.Structural basis of thiamine pyrophosphate analogues binding to the eukaryotic riboswitch.J.Am.Chem.Soc.130,8116-8117(2008). 30.Busan,S.& Weeks,K.M.Accurate detection of chemical modifications in RNA by mutational profiling(MaP) with ShapeMapper 2.RNA 24,143-148(2018). 31.Woolson,R.Statistical Methods for the Analysis of Biomedical Data.(John Wiley & Sons,1987). 32.Jhoti,H.,Williams,G.,Rees,D.C.& Murray,C.W.The ‘rule of three’ for fragment-based drug discovery:Where are we now? Nat.Rev.Drug Discov.12,644(2013). 33.Chen,L.et al.Probing riboswitch-ligand interactions using thiamine pyrophosphate analogues.Org.Biomol.Chem.10,5924-5931(2012). 34.Warner,K.D.& Ferre-D’Amare,A.R.Crystallographic analysis of TPP riboswitch binding by small-molecule ligands discovered through fragment-based drug discovery approaches.Methods Enzymol.549,221-233(2014). 35.Codd,R.Traversing the coordination chemistry and chemical biology of hydroxamic acids.Coord.Chem.Rev.252,1387-1408(2008). 36.Jencks,W.P.On the attribution and additivity of binding energies.Proc.Natl.Acad.Sci.U.S.A.78,4046-4050(1981). 37.Olejniczak,E.T.et al.Stromelysin inhibitors designed from weakly bound fragments:Effects of linking and cooperativity.J.Am.Chem.Soc.119,5828-5832(1997). 38.Borsi,V.,Calderone,V.,Fragai,M.,Luchinat,C.& Sarti,N.Entropic contribution to the linking coefficient in fragment based drug design:A case study.J.Med.Chem.53,4285-4289(2010). 39.Reuter,J.S.& Mathews,D.H.RNAstructure:software for RNA secondary structure prediction and analysis.BMC Bioinformatics 11,129(2010). 40.Busan,S.,Weidmann,C.A.,Sengupta,A.& Weeks,K.M.Guidelines for SHAPE Reagent Choice and Detection Strategy for RNA Structure Probing Studies.Biochemistry 58,2655-2664(2019). 41.Gilbert,S.D.& Batey,R.T.Monitoring RNA-ligand interactions using isothermal titration calorimetry.Methods Mol.Biol.540,97-114(2009). 42.Turnbull,W.B.Divided We Fall? Studying low affinity fragments of ligands by ITC.Microcal Application Notes(2005). 43.Otwinowski,Z.& Minor,W.Processing of X-ray diffraction data collected in oscillation mode.Methods Enzymol.(1997).doi:10.1016 / S0076-6879(97)76066-X. 44.Liebschner,D.et al.Macromolecular structure determination using X-rays,neutrons and electrons:recent developments in Phenix.Acta Crystallogr.75,861-877(2019). 45.Hajduk,P.J.et al.Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR.J.Am.Chem.Soc.119,5818-5827(1997). 46.Howard,N.et al.Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors.J.Med.Chem.49,1346-1355(2006). 47.Barker,J.J.et al.Discovery of a novel Hsp90 inhibitor by fragment linking.ChemMedChem 5,1697-1700(2010). 48.Mobitz,H.et al.Discovery of Potent,Selective,and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.ACS Med.Chem.Lett.8,338-343(2017). 49.Hung,A.W.et al.Application of fragment growing and fragment linking to the discovery of inhibitors of mycobacterium tuberculosis pantothenate synthetase.Angew.Chemie-Int.Ed.48,8452-8456(2009). 50.Jordan,J.B.et al.Fragment-Linking Approach Using19F NMR Spectroscopy to Obtain Highly Potent and Selective Inhibitors of β-Secretase.J.Med.Chem.59,3732-3749(2016). 51.Maly,D.J.,Choong,I.C.& Ellman,J.A.Combinatorial target-guided ligand assembly:Identification of potent subtype-selective c-Src inhibitors.Proc.Natl.Acad.Sci.97,2419-2424(2000). 52.Shuker,S.B.,Hajduk,P.J.,Meadows,R.P.& Fesik,S.W.Discovering High-Affinity Ligands for Proteins:SAR by NMR.Science(80-.).274,1531-1534(1996). 53.Mondal,M.et al.Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin:Fragment-Based Drug Design Facilitated by Dynamic Combinatorial Chemistry.Angew.Chemie-Int.Ed.55,9422-9426(2016). 54.Swayze,E.E.et al.SAR by MS:A ligand based technique for drug lead discovery against structured RNA targets.J.Med.Chem.45,3816-3819(2002).

Claims

1. A compound having the structure of formula (III) or a pharma- ceutically acceptable salt thereof: 【Chemistry 5】 During the ceremony, L is, 【Chemistry 2】 is selected from wherein q and r are independently selected from integers 0, 1, 2, and 3; and z is selected from integers 1, 2, and 3; A is, 【Chemistry 3】 is selected from In the formula, X 5 is N; 4 , X 6 , and X 7 is CR 3 and R 3 is —H; m is 1 or 2; W is -O or -NR 4 and R 4 is -H and substituted or unsubstituted C 1 ~C 6 is selected from alkyl.

2. The compound of claim 1, wherein q and r are independently selected from integers 0, 1, and 2.

3. L, 【Chemistry 7】 3. The compound according to claim 1 or 2,

4. The compound according to any one of claims 1 to 3, wherein q and r are 0 or 1.

5. The compound according to any one of claims 1 to 4, wherein q and r are 1.

6. The compound according to any one of claims 1 to 4, wherein q is 1 and r is 0.

7. The compound according to any one of claims 1 to 6, wherein m is 1.

8. The compound of any one of claims 1 to 7, wherein W is selected from -NH and -O.

9. The compound of any one of claims 1 to 8, wherein W is -NH.

10. A, 【Chemistry 8】 The compound according to any one of claims 1 to 9,

11. A is 【Chemistry 10】 The compound according to any one of claims 1 to 9,

12. The compound has the following structure: 【Chemistry 9】 2. The compound of claim 1 having the formula:

13. The compound according to claim 1, wherein q is 0 and r is 2.

14. L is 【Chemistry 11】 and z is 2.

15. A is 【Chemistry 12】 15. The compound according to claim 13 or 14, 16. The compound of claim 1 having the structure: 【Chemistry 13】

17. The compound of any one of claims 1 to 16, wherein the compound binds to a region of an RNA molecule.

18. The compound of claim 17 , wherein the RNA molecule is a non-coding RNA molecule.

19. 19. The compound of claim 18, wherein the non-coding RNA molecule is selected from rRNA, microRNA, siRNA, piRNA, snoRNA, snRNA, exRNA, and scaRNA.

20. The compound of claim 17, wherein the RNA molecule is a coding RNA molecule.

21. The compound of claim 20, wherein the coding RNA molecule is mRNA.

22. The compound of claim 17 , wherein the region of the mRNA is a riboswitch.

23. 23. The compound of claim 22, wherein the riboswitch is a TPP riboswitch.

24. The compound has a K d A compound according to any one of claims 17 to 23, which exhibits binding affinity.

25. A composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 16 in a pharma- ceutically acceptable carrier, diluent, or excipient.

26. A medicament for treating a disease or disorder associated with dysfunction of RNA expression, comprising a therapeutically effective amount of a compound according to any one of claims 1 to 16 or a composition according to claim 25.

27. 27. The method of claim 26, wherein administering the medicament reduces protein expression due to binding of the compound to RNA.

28. 28. The pharmaceutical of claim 26 or 27, wherein the disease or disorder is selected from a genetic disease, a degenerative disorder, cancer, diabetes, an autoimmune disorder, a cardiovascular disorder, a coagulation disorder, an eye disease, an infectious disease, and a disease caused by mutations in one or more genes.

29. 29. The medicament of claim 28, wherein the disease or disorder is a genetic disease and administering the medicament switches on or off expression of a therapeutic gene.

30. The method further comprising: a) contacting a fragment of formula IV' with a fragment of formula V-1 or V-2 in the presence of a Pd catalyst; or b) contacting a fragment of formula IV' with a fragment of formula VI-1 or VI-2 in the presence of a reducing agent; or A method of making a compound according to any one of claims 1 to 16, comprising: c) contacting a fragment of formula IV' with a fragment of formula VII-1 or VII-2 in the presence of a base. 【Chemistry 14】 【Chemistry 15】 wherein X is a halogen selected from F, Br, Cl, and I; and X 4 , X 5 , X 6 , X 7 , m, and W are as defined in claim 1. 【Chemistry 16】 (wherein X 4 , X 5 , X 6 , X 7 , m, and W are as defined in claim 1 .) 【Chemistry 17】 wherein X 4 , X 5 , X 6 , X 7 , m, and W are as defined in claim 1, and G is -F, -Cl, -Br, -OH, -OCH 3 , or -OCH 2 CH 3 .

Citation Information

Patent Citations

  • Vanilloid receptor ligands and their use in therapy

    JP2007522233A

  • IDO inhibitors

    JP2011505379A

  • Phthalazine derivatives

    WO2008061108A2

Cited By

  • RNA-targeting ligands, compositions thereof, and methods of making and using the same

    US12741945B2